



# Autophagy in healthy aging and disease

Yahyah Aman<sup>1,2,22</sup>, Tomas Schmauck-Medina<sup>1,22</sup>, Malene Hansen<sup>3</sup>, Richard I. Morimoto<sup>4</sup>, Anna Katharina Simon<sup>5</sup>, Ivana Bjedov<sup>2,6</sup>, Konstantinos Palikaras<sup>7</sup>, Anne Simonsen<sup>8,9</sup>, Terje Johansen<sup>10</sup>, Nektarios Tavernarakis<sup>11,12</sup>, David C. Rubinsztein<sup>13,14</sup>, Linda Partridge<sup>15,15</sup>, Guido Kroemer<sup>16,17,18,19,20</sup>, John Labbadia<sup>21</sup> and Evandro F. Fang<sup>1,21</sup> ✉

**Autophagy is a fundamental cellular process that eliminates molecules and subcellular elements, including nucleic acids, proteins, lipids and organelles, via lysosome-mediated degradation to promote homeostasis, differentiation, development and survival. While autophagy is intimately linked to health, the intricate relationship among autophagy, aging and disease remains unclear. This Review examines several emerging features of autophagy and postulates how they may be linked to aging as well as to the development and progression of disease. In addition, we discuss current preclinical evidence arguing for the use of autophagy modulators as suppressors of age-related pathologies such as neurodegenerative diseases. Finally, we highlight key questions and propose novel research avenues that will likely reveal new links between autophagy and the hallmarks of aging. Understanding the precise interplay between autophagy and the risk of age-related pathologies across organisms will eventually facilitate the development of clinical applications that promote long-term health.**

Aging is a biological process that is characterized by time-dependent cellular and functional decline, resulting in reduced quality of life for the organism<sup>1</sup>. In line with this, aging is the primary risk factor for the development of many disorders, including cardiovascular disease (for example, stroke), cancer and neurodegenerative disease (for example, Alzheimer's disease (AD)). Collectively, age-related ailments represent a formidable global socioeconomic burden and a significant health-care challenge<sup>2,3</sup>. Therefore, identifying therapeutic interventions that promote 'healthy aging' (that is, the maintenance of functional ability in old age, enabling older individuals to independently carry out daily tasks) and simultaneously halt the progression of multiple age-related pathological conditions is of paramount importance<sup>2</sup>.

Among the many molecular changes associated with old age, altered autophagy has emerged as a feature of aging across diverse species. However, recent advances in understanding the numerous substrates of autophagy and the temporal and spatial effects of impaired autophagy regulation on tissue homeostasis have revealed a complex and multifactorial relationship between autophagy and aging. Here we examine the relationship among autophagy, aging and disease and propose novel links between specific autophagic

processes and long-term tissue health, as well as possible implications for anti-aging therapeutic interventions.

## Compromised autophagy is a hallmark of aging

Research over the last decade has revealed that the process of autophagy can take many different forms. Autophagy (from the Greek words *auto*, meaning 'self', and *phagein*, meaning 'to eat') is a highly conserved pathway that degrades cellular components, such as defective organelles and aggregates of misfolded protein<sup>4</sup>, through lysosomes. The process of autophagy was first described in the 1960s, but it was the identification of autophagy-related genes (ATG genes) in the 1990s that propelled major breakthroughs in unravelling the mechanistic complexities of autophagy<sup>5–12</sup>. There are three major types of autophagy: macroautophagy, microautophagy and chaperone-mediated autophagy (CMA) (Fig. 1a–c), all of which involve delivery of substrates to the lysosome for degradation (see detailed reviews in refs. <sup>13,14</sup>). Macroautophagy (hereafter referred to as autophagy) was originally thought of as a nonselective bulk degradation process (Fig. 1a, pathway (1)). However, the discovery of selective autophagy receptors, among which p62/SQSTM1 was the first, changed this notion<sup>15,16</sup>. Today, autophagy is recognized as a highly selective cellular clearance pathway that is associated with

<sup>1</sup>Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, Lørenskog, Norway. <sup>2</sup>Institute of Healthy Ageing, Department of Genetics, Evolution and Environment, University College London, London, UK. <sup>3</sup>Development, Aging and Regeneration Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA. <sup>4</sup>Department of Molecular Biosciences, Rice Institute for Biomedical Research, Northwestern University, Evanston, IL, USA. <sup>5</sup>Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK. <sup>6</sup>UCL Cancer Institute, University College London, London, UK. <sup>7</sup>Department of Physiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. <sup>8</sup>Department of Molecular Medicine, Institute of Basic Medical Sciences and Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, The University of Oslo, Oslo, Norway. <sup>9</sup>Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Montebello, Oslo, Norway. <sup>10</sup>Molecular Cancer Research Group, Institute of Medical Biology, University of Tromsø–The Arctic University of Norway, Tromsø, Norway. <sup>11</sup>Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology–Hellas, Heraklion, Greece. <sup>12</sup>Department of Basic Sciences, School of Medicine, University of Crete, Heraklion, Greece. <sup>13</sup>Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, UK. <sup>14</sup>UK Dementia Research Institute, University of Cambridge, Cambridge, UK. <sup>15</sup>Department of Biological Mechanisms of Ageing, Max Planck Institute for Biology of Ageing, Cologne, Germany. <sup>16</sup>Centre de Recherche des Cordeliers, Equipe Labellisée par la Ligue contre le Cancer, Université de Paris, Sorbonne Université, INSERM U1138, Institut Universitaire de France, Paris, France. <sup>17</sup>Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France. <sup>18</sup>Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France. <sup>19</sup>Suzhou Institute for Systems Medicine, Chinese Academy of Medical Sciences, Suzhou, China. <sup>20</sup>Karolinska Institute, Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden. <sup>21</sup>The Norwegian Centre on Healthy Ageing (NO-Age), Oslo, Norway. <sup>22</sup>These authors contributed equally: Yahyah Aman, Tomas Schmauck-Medina. ✉e-mail: [j.labbadia@ucl.ac.uk](mailto:j.labbadia@ucl.ac.uk); [e.f.fang@medisin.uio.no](mailto:e.f.fang@medisin.uio.no)

the maintenance of cellular and tissue homeostasis<sup>17,18</sup>. Selective autophagy can be further divided into many subtypes on the basis of the specific cargos involved. These subtypes target various macromolecules (glycophagy and lipophagy) (Fig. 1a, pathways (2)–(5)), mitochondria (mitophagy) (Fig. 1a, pathway (6)), the endoplasmic reticulum (ER) (ER-phagy) (Fig. 1a, pathway (7)), parts of the nucleus (nucleophagy) (Fig. 1a, pathway (8)), pathogens (xenophagy) (Fig. 1a, pathway (9)) and lysosomes themselves (lysophagy) (Fig. 1a, pathway (10)). Below we will discuss the links among these selective autophagy pathways, aging and disease. The core process of autophagy has been described in detail elsewhere<sup>14,19</sup>. However, in brief, the core process is initiated following inhibition of mechanistic target of rapamycin (mTOR) or activation of 5' AMP-activated protein kinase (AMPK), both of which are canonical inducers of autophagy in response to stress (for example, starvation or elevated temperatures) and physical exercise. In addition, transcription factor EB (TFEB) is an important positive regulator of autophagy and lysosomal biogenesis whose nuclear translocation is coupled to the activity of both mTOR (via phosphorylation) and AMPK (via folliculin (FLCN))<sup>20–23</sup>. Upon activation of autophagy, the process is initiated by membrane nucleation and phagophore formation followed by elongation and maturation before autophagosome fusion with the lysosome for cargo degradation and recycling. The key proteins involved in each step are presented in Fig. 2.

A growing body of evidence suggests that autophagic activity declines with age in diverse organisms<sup>1</sup>. Studies in *Caenorhabditis elegans*, rodents and human cells have demonstrated an age-dependent reduction in lysosomal proteolytic function that thereby impairs autophagic flux<sup>24–27</sup>, exacerbating cellular impairment and contributing to the development of age-related diseases<sup>1,28,29</sup>. Further evidence stemming from *Drosophila* has demonstrated that aging

is associated with reduced expression of several *Atg* genes (*Atg2*, *Atg8a* and *bchs* (encoding blue cheese)), which are pivotal for both autophagy initiation and activity<sup>30</sup>. In aged wild-type mice, autophagy is diminished in neuronal cells, as evidenced by decreased rates of autophagolysosomal fusion and impaired delivery of autophagy substrates to lysosomes in the hypothalamus<sup>31</sup>. Moreover, a decrease in autophagic processes was observed in brain tissue from 18- to 25-month-old mice, as demonstrated by a reduction in the levels of *Atg5–Atg12* and *Becn1*, elevated mTOR activity and increased levels of ferritin H (ferritin H is mainly removed from cells by the autophagy–lysosome pathway)<sup>32</sup>. In addition, emerging evidence in aged rats has highlighted an age-associated decline in expression of the autophagy-related protein beclin 1 (BECN1) in whole brain tissue, as well as in the hippocampus of naked mole rats and Wistar rats<sup>33,34</sup>. In line with observations in rodent models, findings in humans have suggested that the expression of autophagy-related genes, such as *ATG5*, *ATG7* and *BECN1*, declines with age<sup>35</sup>. Moreover, the development and progression of several human pathologies is highly associated with age-dependent autophagy deficits<sup>19,36,37</sup>. Collectively, these studies demonstrate that a gradual decline in the abundance of autophagy-related proteins and reduced delivery of cargo to lysosomes occur with age, implicating compromised autophagy as a cardinal feature of organismal aging.

In line with a causal role for autophagy in the aging process<sup>14</sup>, genetically impairing nonselective or selective autophagy results in accelerated tissue functional decline and disease in a range of experimental models. Transcriptomic profiling in *Saccharomyces cerevisiae* has provided evidence of defective autophagy among short-lived as compared to long-lived mutants<sup>38</sup>. In addition, selective mutation(s) and/or knockdown of genes encoding components of the autophagic machinery in *C. elegans* (*lgg-1* (ortholog of


**Fig. 1 | Different mechanisms of autophagy.** **a**, Macroautophagy (referred to herein as autophagy) (1) is a nonselective process that targets macromolecules or subcellular organelles in bulk. Cytoplasmic material is sequestered into an autophagosome and delivered to the lysosome (or endolysosome) for degradation). Selective autophagy involves recognition of specific cytoplasmic cargo via autophagy receptors that also interact with LC3 in the autophagic membrane, leading to cargo sequestration into autophagosomes that are delivered to a lysosome (or endolysosome) for degradation. This includes aggrephagy (2), where aggregated proteins are ubiquitinated and targeted by ubiquitin-binding autophagy receptors such as p62 (or NBR1); glycophagy (3), where STBD1 (genethonin-1) binds to glycogen and GABARAP, facilitating lysosomal glycogen breakdown into non-phosphorylated glucose by enzymes such as GAA; lipophagy (4), in which lysosomal lipids are degraded into free fatty acids, which are then converted into ATP; the identity of the receptor(s) (yellow) involved in sequestration of lipid droplets is unknown; granulophagy (5), where sequestration of stress granules (RNA + protein) is mediated by Cdc48/VCP, allowing the stress granule to be delivered to the lysosome for degradation; mitophagy (6), where damaged mitochondria are bound by soluble or membrane-bound mitophagy receptors (mReceptors) that can also bind LC3, leading to engulfment of the mitochondrion into an autophagosome and subsequent delivery to a lysosome for degradation (left); in piecemeal mitophagy, degradation of parts of mitochondria occurs via binding of the outer mitochondrial membrane protein metaxin-1 (MTX1, in the extruded fraction) to LC3C, resulting in the recruitment of p62 and autophagosome formation (right); ER-phagy (7), which in mammals uses the specific receptors FAM134B, RTN3L, ATL3, SEC62, CCP1 and TEX264, which are located in different parts of the ER; these receptors bind to LC3, leading to sequestration of the ER into an autophagosome and lysosomal degradation of the ER; nucleophagy (8), which, when triggered in mammals, results in nuclear LC3 binding to lamin B1, leading to formation of a bulge that is pinched off to the cytoplasm where degradation by autophagy occurs; xenophagy (type A, 9), where a bacterium's DNA is detected by cGAS, a sensor that triggers a process of ubiquitination via Smurf1; this is followed by attachment of the NBR1 receptor to the ubiquitin chains and LC3 to continue the autophagy process for degradation of the bacterium; xenophagy (type B, 10), where a bacterium damages the membrane of the phagosome, exposing interior glycans that recruit galectin-8 (Gal-8), which is then recognized by NDP52 to recruit TBK1, LC3C, Nap and Sintbad; the optineurin, p62 and NDP52 receptors interact with ubiquitin on the pathogen and recruit the autophagic engulfment system, and the engulfed pathogen is then brought for degradation; and lysophagy (11), which occurs upon lysosomal membrane permeabilization and can be achieved with or without ubiquitination: recruitment of galectin-3 (Gal-3) to damaged lysosomes further recruits TRIM16 and autophagic proteins such as ULK1 and ATG16L1, and ubiquitination on the lysosome results in the recruitment of p62, which binds to LC3 to facilitate the autophagic process (left); in a parallel ubiquitin-independent process, galectin-8 is recruited to damaged lysosomes and is capable of directly binding to the NDP52 receptor that interacts with LC3 to continue the autophagic process (right). **b**, Microautophagy involves capture of cytoplasmic components through direct invagination of endolysosome membranes and can be nonspecific (bulk) (12) or highly specific (13,14). Examples of selective microautophagy in mammalian cells include micro-ER-phagy (13), which uses the SEC62 receptor and involves ER capture and degradation by invagination of the lysosome/endolysosome, and endosomal microautophagy of proteins with the KFERQ pentapeptide motif (14) in a process requiring the chaperone HSC70. **c**, CMA (15) also involves targeting of proteins containing a KFERQ pentapeptide-related motif by HSC70 and other co-chaperones such as HSP40. The substrate is then imported into the lysosome through the LAMP2A receptor for further degradation. The LAMP2A receptor is modulated by the glial fibrillary acidic protein (GFAP). Finally, in a CMA-like manner, DNAutophagy/RNAutophagy (16) can occur: nucleic acids (DNA or RNA) bind to the LAMP2C receptor (orange), which also binds to lysosomes. This process allows nucleic acids to be taken up by the lysosome. It has been proposed that a transporter called SIDT2 (green) might have a role in direct uptake of nucleic acids by the lysosome.


*ATG8*), *unc-51* (ortholog of *ATG1*), *bec-1*, *atg-7*, *lgg-3* (also known as *atg-12*) and *atg-18*), *Drosophila* (*Atg3* and *Atg8a*) and mice (*Atg5*, *Atg7* and *Becn1*) shorten lifespan and healthspan<sup>1,14,30,39</sup>. In line with these observations, systemic genetic knockout of autophagy components (*Becn1*, *Atg5*, *Atg9* and *Atg13*) is lethal in mice, highlighting the importance of autophagy in development<sup>40</sup>. Furthermore, knockdown of genes encoding transcription factors that regulate autophagy, such as *TFEB* (ortholog in *C. elegans*, *hlh-30*) and *FOXO* (encoding forkhead box O; ortholog in *C. elegans*, *daf-16*) shortened lifespan in both wild-type worms and long-lived *daf-2* (insulin/insulin-like growth factor-1 (IGF-1) receptor) mutants<sup>41</sup>.

In contrast, studies in long-lived mutant animals have shown that increased autophagy is associated with delayed aging. In particular, the extended lifespan of *C. elegans daf-2* loss-of-function mutants is dependent on autophagic genes, such as *bec-1*, *lgg-1*, *atg-7* and *atg-12* (refs. <sup>1,14,42</sup>). Furthermore, HLH-30 is required for the

long lifespan of multiple longevity mutants, including not only *daf-2* mutants with reduced insulin/insulin-like signaling, but also germline-less *glp-1(e2141)* mutants, dietary-restricted *eat-2(ad1116)* mutants, mitochondrial respiration-defective *clk-1(e2519)* mutants and mRNA translation-impaired *rsks-1(sv31)* mutants<sup>43</sup>. These findings coincide with impaired induction of autophagosome formation and lysosomal degradation upon loss of *hlh-30*, suggesting that HLH-30 promotes longevity by regulating the autophagy process downstream of multiple lifespan extension paradigms<sup>43</sup>. In addition, formation of long-lived dauer worms, corresponding to a larval hibernation stage, is also associated with increased autophagy and is dependent on the autophagy genes *atg-1*, *atg-7*, *lgg-1* and *atg-18*, underlining the essential role of autophagy in organismal adaptation during challenging conditions<sup>42</sup>.

In line with observations from long-lived mutants, genetic or pharmacological upregulation of autophagy promotes longevity in





**Fig. 2 | Core machinery of autophagy.** Initiation of autophagy requires the ULK1 kinase complex, which is tightly regulated by AMPK and mTOR, which act as an activator and inhibitor, respectively. AMPK activates ULK1 through phosphorylation. The ULK1 complex, composed of FIP200, ATG13 and ATG101, stimulates the class III phosphatidylinositol 3-kinase (PIK3C3) complex, which is composed of BECN1 (which can be inhibited by BCL-2), AMBRA1, ATG14L, VPS15 and VPS34. This complex then produces a pool of phosphatidylinositol 3-phosphate (PtdIns3P), which leads to the recruitment of WIPI proteins, which recover ATG9-positive vesicles from previous membranes, as well as recruiting the ATG5-ATG12-ATG16L1 (E3) complex. LC3 is first cleaved by the ATG4 protease to form cytosolic LC3-I, which is further recognized by E1 (ATG7), E2 (ATG3) and E3 components, leading to its conjugation to phosphatidylethanolamine (PE). After this process, LC3-I is referred to as LC3-II. LC3-II binds to LIR-containing autophagy receptors (AR; such as p62) bound to cargo targeted for degradation. Fusion of autophagosomes with lysosomes is mainly mediated by the assistance of RAB proteins, SNARE proteins and a HOPS complex. After fusion, the cargo is degraded by lysosomal hydrolases and the degradation products can be reused by the cell. LC3-II bound to the outer membrane is cleaved by ATG4 to be reused for a new round of lipidation.

animals. Autophagy induction by overexpression of *Atg* genes in *Drosophila* (*Atg1* and *Atg8a*) and mice (*Atg5*) extends lifespan<sup>30,44,45</sup>. Similarly, *Bcl2* mutations that disrupt the BECN1–BCL-2 complex increase basal autophagic flux, which results in long-lived male and female mice with improved healthspan<sup>46</sup>. Overexpression of autophagic regulators in *C. elegans* and *Drosophila*, such as AMPK, further facilitates autophagy in diverse tissues and in turn extends longevity<sup>14,45</sup>. Additionally, *hh-30* overexpression enhances autophagy and promotes lifespan extension in *C. elegans*<sup>43</sup>, and silencing of the nuclear export protein exportin-1 (XPO-1) enhances autophagy by enrichment of HLH-30 in the nucleus, which is accompanied by proteostatic benefits and improved longevity<sup>47</sup>. Moreover, rapamycin, an inhibitor of the mTOR pathway, has been shown to extend the median and maximum lifespan of both female and male mice when fed to them late in life<sup>48</sup>.

Accumulating evidence in aged mice, as well as in rodent models recapitulating characteristic features of human diseases, has shown that compromised autophagy is among the most common factors contributing to the collapse of tissue homeostasis. In particular, age-associated dysregulation of autophagy (demonstrated by the accumulation of autophagosomes), possibly due to impaired lysosomal fusion and/or degradation, is associated with cellular dysfunction and/or death, which contribute to neurodegeneration, as well as cardiac and skeletal muscle aging<sup>49–53</sup>. In hematopoietic stem cells (HSCs), autophagy has been shown to delay aging via activation of downstream sirtuin-3 (SIRT3), a key mitochondrial protein capable of rejuvenating blood and protecting against oxidative stress in mice and human HSC-enriched cells<sup>54</sup>.

Moreover, autophagy appears to be a critical mechanism to maintain immune memory in mice, and levels of the endogenous autophagy-inducing metabolite spermidine fall in human T cells

with age. In fact, supplementation of T cells from older donors with spermidine restores autophagy levels to those observed in younger donors via the eIF5A translation factor and TFEB transcription factor<sup>55</sup>. Furthermore, spermidine administration in a mouse model of mild cognitive impairment, a transitional phase between healthy aging and AD, led to an improvement in degradation of misfolded proteins and an accompanying delay in age-related memory deficits, thereby implicating autophagy as a pathophysiological mechanism of action<sup>56</sup>.

While dysregulation of autophagy underlies aging and disease phenotypes, excessive autophagy may also contribute to the deterioration of cellular function in some contexts. Recent evidence has demonstrated that an age-dependent decline in the levels of Rubicon, a negative regulator of autophagy, exacerbates metabolic disorders in adipocytes<sup>57</sup>. While strongly upregulated autophagy may exacerbate metabolic disorders, this finding may also be attributed to autophagy-independent changes in metabolism. Furthermore, elevated autophagy has been found to shorten lifespan in *C. elegans* mutants lacking *sgk-1* (encoding serum/glucocorticoid-regulated kinase-1). Loss of this kinase results in increased mitochondrial permeability, leading to excessive autophagy and reduced organismal fitness in worms and mice<sup>58</sup>. Conversely, reducing the levels of autophagy in *sgk-1* mutants or suppressing the opening of the mitochondrial permeability transition pore restores normal lifespan<sup>58</sup>. Similarly, suppressing autophagy exclusively in the intestine of post-reproductive adults at higher temperatures has been proposed to prevent the emergence of age-related pathologies in *C. elegans*<sup>59</sup>. However, it should be noted that this is in direct contrast to findings in long-lived mutants, where intestinal autophagy is enhanced<sup>60,61</sup>. Another study in *C. elegans* showed that short interfering RNA (siRNA)-based reduction in the abundance of the

**Table 1 | Summary of autophagy factors that can promote longevity**

Protein	Function	Effect of modification on longevity
Y: ATG1; W: UNC-51; F: Atg1; M: ULK1; H: ULK1	Kinase required for formation of the autophagosome <sup>217</sup>	W: Mutations in the gene (whole life) cause the organism to age faster <sup>39</sup> ; F, Y, W: essential for longevity when using approaches such as mTOR suppression, overexpression of AMPK, dietary restriction, rapamycin and others <sup>39,45,218,219</sup>
Y: ATG2; W: ATG-2; F: Atg2; M: ATG2A and ATG2B; H: ATG2A and ATG2B	Lipid transport protein crucial for formation of the autophagosome <sup>220</sup>	F: Knockdown reduces lifespan <sup>221</sup> ; levels significantly decrease with age <sup>30</sup>
Y: ATG4; W: ATG-4.1 and ATG-4.2; F: Atg4b; M: ATG4A to ATG4D; H: ATG4A to ATG4D	Protease required for conjugation/deconjugation of PE to ATG8 proteins <sup>222</sup>	W: Essential for longevity when using approaches such as <i>mir-34</i> loss of function <sup>223</sup>
Y: ATG5; W: ATG-5; F: Atg5; M: ATG5; H: ATG5	Part of the E3 complex required for ATG8 lipidation <sup>224</sup>	M: Ubiquitous overexpression in transgenic mice increases lifespan <sup>44</sup> ; F, Y: gene is essential for longevity induced by methionine restriction and rapamycin <sup>225,226</sup>
Y: Vps30/ATG6; W: BEC-1; F: Atg6; M: BECN1; H: BECN1	Subunit of the class III PI3K complex required for autophagosome formation <sup>224</sup>	F, W, Y: Mutations in the gene (whole life) cause the organism to age more rapidly; essential for longevity when using approaches such as mTOR suppression, <i>mir-34</i> loss of function, treatment with spermidine and urolithin A, and dietary restriction <sup>39,61,199,207,223,227</sup>
Y: ATG7; W: ATG-7; F: Atg7; M: ATG7; H: ATG7	E1 enzyme required for ATG8 lipidation <sup>224</sup>	M, W: Absence of the gene decreases lifespan and increases atrophy and inflammation <sup>181,228</sup> ; F, W, Y: important for longevity when using approaches such as treatment with spermidine, dietary restriction and methionine restriction <sup>199,225,227</sup> ; H: significantly reduced in the muscles of sarcopenic adults <sup>181</sup> ; M: significantly reduced in the muscles of aged mice <sup>181</sup>
Y: ATG8; W: LGG-1 and LGG-2; F: Atg8a; M: LC3/GABARAP; H: LC3/GABARAP	Small ubiquitin protein conjugated to PE in autophagic membranes; interacts with proteins containing AIM or LIR motifs	F: Overexpression in neurons increases lifespan <sup>30</sup> ; F, overexpression in muscles increases lifespan <sup>180</sup> ; F: mutations in the gene produce neurodegeneration and reduce lifespan <sup>30</sup> ; Y: essential for longevity when using approaches such as methionine restriction <sup>225</sup> ; F: crucial for formation of the autophagosome; at week 4, it is downregulated up to 60% (ref. <sup>30</sup> )
Y: ATG9; W: ATG-9; F: Atg9; M: ATG9A; H: ATG9A	Transmembrane protein required for autophagosome formation <sup>229</sup>	W: Essential for longevity when using approaches such as <i>mir-34</i> loss of function <sup>223</sup>
Y: ATG12; W: LGG-3; F: Atg12; M: ATG12; H: ATG12	Forms a complex with ATG5 and ATG16L1 (W: ATG-16.1; H + M: ATG16L1) <sup>230</sup>	W: Reduced expression from egg lay (RNAi) reduces lifespan <sup>228</sup>
Y: ATG15; W: ?; F: ?; M: ?; H: ?	Required for lysis of subvacuolar vesicles <sup>231</sup>	Y: Essential for longevity when using approaches such as dietary restriction <sup>232</sup>
Y: ATG18; W: ATG-18; F: Atg18; M: WIPI-1 and WIPI-2; H: WIPI-1 and WIPI-2	PtdIns3P-binding protein essential for autophagy <sup>233</sup>	W: Mutations in the gene (whole life) cause the organism to age more rapidly and loss of function reduces lifespan <sup>28,39</sup> ; its expression in neurons and intestine is essential for maintaining wild-type lifespan <sup>179</sup> ; reduced expression of S6K increases its levels <sup>234</sup> ; essential for longevity when using approaches such as mTOR suppression and dietary restriction <sup>39,179</sup> ; F: significantly decreases in abundance with age <sup>30</sup>
Y: ?; W: PDR-1; F: parkin; M: parkin; H: PRKN	Ubiquitin E3 ligase that ubiquitinates outer mitochondrial membrane proteins, promoting mitophagy <sup>235</sup>	F: Overexpression ubiquitously or in neurons (during aging) increases lifespan <sup>236</sup>
Y: ?; W: PINK-1; F: Pink1; M: PINK1; H: PINK1	Mitochondrial kinase that phosphorylates ubiquitin and recruits parkin upon mitochondria depolarization <sup>237</sup>	W: Essential for longevity when using multiple approaches, such as nicotinamide riboside and urolithin A treatment, among others <sup>140,207,238</sup>
Y: ?; W: SQST-1; F: ref(2)P; M: p62 and NBR1; H: p62/SQSTM1 and NBR1 (many other receptors exist)	Ubiquitin-binding autophagy receptor involved in selective autophagy <sup>239</sup>	W: Strains that overexpress the gene have increased lifespan <sup>76,77</sup> ; essential for longevity and for lifespan and healthspan improvements from mitophagy inducers (for example, urolithin A) <sup>76,207,238</sup>
Y: ?; W: HLH-30; F: MITF; M: TFEB; H: TFEB	Transcription factor for genes involved in autophagy, the lysosome and phagocytosis <sup>43</sup>	W: Strains with overexpression have increased lifespan <sup>43</sup>
Y: VPS34; W: VPS-34; F: Pi3K59F; M: VPS34; H: PIK3C3	PI3K required for autophagosome formation <sup>240</sup>	W: Essential for longevity when using multiple approaches, such as urolithin A treatment and dietary restrictions <sup>61,207</sup>

Y, yeast; W, worms; F, flies; M, mice; H, humans.

VPS-34–BEC-1–EPG-8 autophagic nucleation complex in aged post-reproductive worms extended lifespan and improved neuronal integrity<sup>29</sup>. However, detailed data on knockdown efficiency in aged worms, as well as an understanding of the remaining levels of neuronal autophagy, are necessary to ensure accurate in-depth data interpretation. Collectively, these observations suggest that maintenance of functional autophagy is essential for healthy cellular and organismal aging and that dysregulation of autophagy in either direction, whether insufficient or excessive, contributes to cellular deficits and functional organismal decline.

A summary of autophagy-related genes linked to longevity and disease is provided in Table 1 and Supplementary Table 1. In addition, several interventions known to promote lifespan, including dietary restriction and treatment with pharmacological agents, such as rapamycin, spermidine and NAD<sup>+</sup> precursors, require intact autophagic machinery. In totality, these findings reinforce the notion that autophagy stimulation is necessary and sufficient to sustain organismal homeostasis and extend longevity in multiple model organisms (discussed in detail below)<sup>1</sup>. An overview of autophagy inducers linked to enhanced longevity and improved health is presented in Table 2.

Together, numerous studies have provided evidence that (1) autophagy is compromised during the process of aging; (2) dysfunction of autophagy shortens lifespan in various experimental animal models; and (3) promotion or restoration of autophagy contributes to lifespan and healthspan extension in diverse organisms. This suggests that autophagy is a central regulator of aging. However, an important and fundamental question remains unanswered: how does autophagy facilitate long-term cell and tissue health?

## The multifaceted role of autophagy in health and aging

**Autophagy and protein homeostasis.** Protein homeostasis (proteostasis) collapse is a central hallmark of aging and disease that is characterized by the appearance of misfolded, mislocalized and aggregated proteins. While age-related loss of proteostasis has been documented in numerous tissues, age-dependent protein aggregation is strongly linked to neurodegenerative pathologies such as AD, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis (ALS)<sup>62,63</sup>.

Along with molecular chaperones and the ubiquitin–proteasome system (UPS), autophagy is a central regulator of cellular proteostasis that operates to (1) degrade soluble misfolded or oligomeric proteins via CMA (the selective degradation of ubiquitin-tagged protein aggregates by chaperone-assisted selective autophagy) and (2) remove bulk protein aggregates<sup>13,19,64</sup>. In line with this, genetic perturbation of core components or regulators of the autophagy machinery accelerates age-related protein aggregation, shortens lifespan and exacerbates pathological features in worm, fly and mouse models of disease. Conversely, increasing autophagy, genetically or pharmacologically, suppresses protein aggregation and promotes health and longevity<sup>48,65,66</sup> (also reviewed in refs. 67–69).

In *C. elegans*, loss-of-function mutations in *bec-1* or *atg-18* or RNA interference (RNAi) against *bec-1*, *atg-9* or *lgg-1* increases susceptibility to protein aggregation, accelerates the onset of age-related paralysis and shortens lifespan<sup>39,70</sup>. Similarly, mutations in the core autophagy components *Atg8a* or *Atg7* in *Drosophila* increase the levels of insoluble protein aggregates and reduce longevity<sup>30,71</sup>. Finally, knockout of *Atg5* or *Atg7* in mouse neurons leads to the appearance of cytoplasmic inclusion bodies in the brain and early-onset neurodegeneration<sup>72–74</sup>, while knockout of *Lamp2* (the primary receptor for CMA) in the liver results in altered proteostasis and hepatic dysfunction with age<sup>75</sup>.

Conversely, enhanced proteostasis and extended lifespan in *C. elegans* occur when the lysosome–autophagy transcription factor HLH-30 or the selective autophagy receptor p62/SQSTM-1 is upregulated. Likewise, in *Drosophila*, overexpression of Ref(2)P (p62

ortholog) or the autophagy activator FOXO reduces protein aggregation in various tissues and extends lifespan<sup>43,76–79</sup>. Pharmacological (for example, via clonidine, rilmenidine or rapamycin) or genetic (for example, *atg5*) upregulation of autophagy in zebrafish harboring the rare p.Ala152Thr variant of tau ameliorates tau pathology<sup>80</sup>. Increased autophagy is also associated with enhanced clearance of protein aggregates in mammals, as systemic overexpression of *Atg5* or *Becn1* genes with mutations that disrupt BECN1–BCL-2 binding improves proteostasis and promotes longevity in mice<sup>44,81</sup>, while overexpression of the selective autophagy mediator BAG3 suppresses tau accumulation in neurons<sup>82</sup>.

As a complement to the genetic modulation of autophagy, treatment of *Drosophila* with the mTOR inhibitor rapamycin suppresses age-related protein aggregation and extends lifespan in an autophagy-dependent manner<sup>83</sup>. Furthermore, in cell culture and fly models, rapamycin suppresses toxicity from neurodegenerative disease-associated proteins, including mutant huntingtin, polyalanine-expansion-containing proteins and tau<sup>84</sup>. Several other pharmacological autophagy inducers, such as spermidine and nicotinamide, have also been reported to protect against proteostasis collapse and proteotoxicity in various models of Huntington's disease, AD, Parkinson's disease and ALS<sup>67</sup>.

Autophagy has also been linked to stem cell function, with the autophagy-mediated clearance of protein aggregates central to the activation of quiescent neuronal stem cells. Activating autophagy by overexpression of TFEB or rapamycin supplementation inhibits age-related protein aggregation and enhances neuronal and muscle stem cell function in aged mice<sup>85–87</sup>. Given the fact that stem cell exhaustion is intimately linked to age-related tissue dysfunction, these findings suggest that enhancing proteostasis specifically in stem cells may preserve many aspects of healthy tissue function during aging. Collectively, these observations strongly support the notion that autophagy promotes healthy aging by protecting cells against toxic misfolded and aggregated proteins.

**Autophagy regulation of macromolecule availability.** Another important role for autophagy in cellular homeostasis and organismal aging is to ensure the availability of metabolites, including amino acids, lipids, carbohydrates and nucleic acids, especially during states of stress, such as nutrient starvation (Fig. 1a). Under challenging conditions, autophagy promotes cellular metabolism and survival by recycling amino acids, which are generated from the degradation of cytosolic substrates, to replenish nutrients, produce energy and promote protein synthesis. An inability to properly recycle amino acids through autophagy is linked to growth and developmental defects in *Atg5*-deficient mice and impaired growth during nitrogen starvation in several *atg*-deficient yeast cell lines (including *atg1Δ*, *atg2Δ*, *atg7Δ*, *atg11Δ*, *atg15Δ* and *atg32Δ* mutants)<sup>88–90</sup>. Autophagy can also be tailored to mediate the availability of carbohydrates, lipids and nucleic acids through three main cellular processes: glycolysis, lipophagy and RNAutophagy or DNAutophagy, respectively.

**Glycolysis.** Glucose is the primary energy source for cellular metabolism. It is stored as glycogen, and metabolism of glucose is tightly regulated in a tissue-dependent manner (that is, the liver maintains blood glucose levels, while muscles are the source of cellular energy). However, various conditions resulting in metabolic stress, such as starvation, stimulate glycogen breakdown to augment cellular glucose levels and promote metabolic activity<sup>91</sup>. Glycogen can be degraded in the cytosol through the activity of glycogen phosphorylase and glycogen debranching enzymes (detailed in ref. 92) or in the lysosome via autophagy. The selective clearance of glycogen via autophagy, referred to as glycolysis, has a crucial role in glucose homeostasis. In response to nutrient deficiency, the energy sensor AMPK is activated, which in turn inhibits mTOR

**Table 2 | Summary of autophagy inducers that extend healthspan and increase lifespan in laboratory animals**

Pharmacological agent	Health benefit	Mode of action
Metformin	W, M: increase in lifespan and healthspan	Activates AMPK and other mechanisms <sup>241</sup> (also reviewed in ref. <sup>242</sup> )
Rapamycin	W, F, M: increase in lifespan and different healthspan parameters	Direct autophagy induction via mTOR inhibition <sup>243</sup> (reviewed in ref. <sup>242</sup> )
Resveratrol	Y, W, F, M: increase in lifespan and different healthspan parameters <sup>9</sup>	SIRT1-dependent induction of autophagy and non-autophagy pathways <sup>112</sup> (reviewed in ref. <sup>68</sup> )
Spermidine	W, F, M, R: increase in median lifespan and different healthspan parameters	Autophagy, anti-inflammation, and arginine and nitric oxide metabolism <sup>196,199</sup>
NR/NMN	W, F, M: increase in lifespan; W, F, M: increase in healthspan; M: increased memory	Pathways dependent and independent of autophagy/mitophagy (reviewed in ref. <sup>185,244</sup> )
Urolithin A	W: increase in lifespan and healthspan; W, M: increased memory	Autophagy/mitophagy induction <sup>138,207,208</sup>
Actinonin	W, M: increased memory	Autophagy/mitophagy-dependent pathway <sup>138</sup>
Tomatidine	W: increase in lifespan and healthspan	Mitophagy induction via the SKN-1-Nrf2 pathway <sup>142</sup>
Trehalose	W: increase in lifespan and healthspan <sup>245</sup>	?
MI	W: increase in lifespan and healthspan	PINK1-dependent mitophagy induction <sup>246</sup>
XPO1 inhibitors	W, F: increase in lifespan and improved conditions in neurodegenerative models	Induction of nuclear localization of HLH-30/TFEB <sup>47</sup>

Y, yeast; W, worms; F, flies; M, mice; R, rats; MI, myoinositol; NR, nicotinamide riboside; NMN, nicotinamide mononucleotide. \*No extension was found in wild-type mice with normal diet, but extended lifespan was observed in mice fed a high-fat diet<sup>12</sup>.

complex 1 (mTORC1), leading to activation of the ULK1 kinase, which is important for induction of autophagy (AMPK–mTORC1–ULK1 triad)<sup>91</sup>. Recent findings in yeast have demonstrated that Atg11 is necessary to facilitate interaction between the AMPK homolog Snf1 and the ULK1 homolog Atg1 upon glucose starvation to promote autophagy<sup>93</sup>. The LC3-interacting region (LIR) motif, also known in yeast as the Atg8-family-interacting motif (AIM), in starch-binding domain-containing protein 1 (STBD1) may allow cells to physically link glycogen to GABARAP1, facilitating the transport of glycogen to lysosomes for degradation (Fig. 1a, pathway (3))<sup>94</sup>. In parallel to glycophyagy, other pathways such as  $\beta$ -oxidation may maintain cellular bioenergetics to compensate for glucose deprivation<sup>95</sup>. Autophagy also has a pivotal role in maintaining cell function, not only in glucose starvation but also in conditions of excess glucose. High glucose levels were associated with mitochondrial dysfunction, generation of reactive oxygen species and induction of autophagy in endothelial progenitor cells<sup>96</sup>.

Under conditions of impaired autophagy, accumulation of glycogen contributes to the pathogenesis of age-related diseases. In Pompe disease, a lysosomal storage disorder, the ability of lysosomes to degrade glycogen is impaired, owing to a deficiency in the lysosomal hydrolytic enzyme acid  $\alpha$ -glucosidase (GAA). This results in accumulation of lysosomal glycogen in many tissues, predominantly in skeletal and cardiac muscle, leading to progressive lethal skeletal myopathy and respiratory and cardiac defects<sup>97</sup>. Impaired tissue function from the inability of lysosomes to degrade glycogen also leads to energy deficiency in skeletal muscle. For infantile-onset Pompe disease<sup>98</sup>, a promising therapeutic intervention is administration of recombinant human GAA. Furthermore, dysfunctional autophagy-mediated accumulation of glycogen has been demonstrated to be the cause of neurodegeneration in a mouse model of Lafora disease, with this accumulation suppressed when glycogen synthase is deleted<sup>99</sup>. These findings indicate that glycogen accumulation might be a cause, rather than a consequence, of impaired autophagy, resulting in impaired cellular function and disease. Glycophyagy, therefore, is essential for cellular function and survival, suggesting that levels of glycophyagy could determine organismal health and possibly longevity.

**Lipophagy.** Intracellular storage and use of lipids is critical to maintain cellular energy homeostasis. In response to starvation, triglycerides stored in lipid droplets are hydrolyzed by specific lipases into free fatty acids for energy metabolism. Lipid droplets can also undergo selective degradation by autophagy, termed lipophagy, as an alternative mechanism for regulating lipid homeostasis (Fig. 1a, pathway (4))<sup>100</sup>. Thus far, a specific receptor coupling lipid droplets to autophagosomes and trafficking to lysosomes has not yet been identified, although LC3-mediated engulfment of lipid droplets has been observed<sup>101</sup>. Moreover, CMA has been implicated in degradation of the lipid droplet-associated proteins perilipin 2 (PLIN2) and perilipin 3 (PLIN3)<sup>102</sup>. Lysosomal acid lipases are involved in the degradation of lipid droplets; in particular, lipolysis is conducted primarily by adipose triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL), and selective knockdown of ATGL and HSL in mice results in selective inhibition of lipid droplet degradation, while other autophagy processes (that is, degradation of proteins and organelles) serve as a compensatory mechanism to replenish the reduced availability of energy substrates<sup>103</sup>. An age-dependent decline in basal autophagy in the liver may underlie the accumulation of hepatic lipids, which in turn has been proposed to contribute to metabolic conditions as well as impairing autophagy, a vicious cycle promoting aging<sup>100</sup>. For example, age-dependent reduction in CMA is likely due to alterations in the lipid composition of discrete microdomains at the lysosomal membrane, including altered dynamics and stability of the CMA receptor LAMP2A in the lysosome<sup>104</sup>. Additional mechanisms by which age-related alterations in lipid composition and/or levels may impair autophagy remain unknown. Further, age-dependent accrual of lipid droplets and ectopic fat deposition are highly interconnected with the age-dependent decline in autophagy and/or autophagic defects<sup>105,106</sup>. Autophagy and LIPL-4-dependent lipolysis are both upregulated in germline-less *C. elegans* and work interdependently to prolong lifespan<sup>107</sup>. The mammalian homolog of worm LIPL-4 is lysosomal acid lipase (LIPA), a key enzyme involved in the hydrolysis of cholesterol via autophagy<sup>108,109</sup>. Cellular supplementation with NAD<sup>+</sup>, which stimulates autophagy and subtypes of autophagy, including mitophagy, and stimulates the activity of the NAD<sup>+</sup>-dependent

sirtuin-1 (SIRT1) and SIRT3 pathways, reduced fat accumulation and increased lifespan in progeroid animals fed a high-fat diet<sup>110–112</sup>, highlighting the importance of autophagic degradation of lipids in healthspan and lifespan.

In pathological conditions such as alcoholic fatty liver disease (AFLD), impaired lipophagy has been shown to be the basis of lipid peroxidation and cellular damage. AFLD results from excessive consumption of alcohol, leading to damage to the liver in the form of oxidative stress, excessive lipid droplet accumulation in the cytoplasm of hepatocytes (steatosis), mitochondrial damage and cell death. Acute exposure to ethanol triggers lipophagy, which acts as a defense mechanism against lipid peroxidation, thereby protecting hepatocytes. However, chronic exposure to ethanol leads to mTOR-mediated inhibition of lipophagy, which in turn contributes to lipid peroxidation and cell death<sup>22,113,114</sup>. In fact, inhibition of mTOR-mediated suppression of TFEB, using torin-1, resulted in enrichment of TFEB levels in the liver and protection against steatosis and ethanol-induced liver injury<sup>115</sup>. Genetic overexpression of TFEB in the liver was shown to increase lysosomal biogenesis and enhance mitochondrial bioenergetics, which served as a protective mechanism against ethanol-induced liver injury in mice. In line with these findings, knockdown of TFEB in the liver of mice resulted in more severe liver injury in response to increased ethanol consumption<sup>115</sup>. In addition, lipophagy is key for the differentiation of several cell types, including hepatocytes<sup>116</sup> and neutrophils<sup>117</sup>. Knocking out ATG7 in HSCs leads to an accumulation of immature neutrophils resembling the myeloid bias of an aging hematopoietic system. Differentiation can be rescued by supplementation with exogenous free fatty acids used for  $\beta$ -oxidation, further demonstrating that lipophagy usually provides these during the energy-intensive process of differentiation. Further studies on the molecular mechanisms of lipophagy, including identification of lipid-specific autophagy receptors and their impact on cellular homeostasis, will shed light on the relationship among autophagy, metabolism and aging.

**Autophagic degradation of nucleic acids: RNAutophagy and DNAutophagy.** Nucleic acids are degraded via multiple mechanisms (a complete description of which is beyond the scope of this Review; see details in refs. <sup>118,119</sup>), including by autophagy. RNA and DNA are targeted for lysosomal degradation via several pathways, including LC3-dependent autophagic degradation of stress granules (condensates of protein and RNA)<sup>120</sup>, p62- and NDP52-dependent autophagic degradation of retrotransposon RNA<sup>121</sup>, lysosomal membrane protein LAMP2C-dependent direct binding to RNA (also DNA<sup>122</sup>) for lysosomal degradation<sup>123</sup> and a lysosomal putative RNA/DNA transporter, SID1 transmembrane family, member 2 (SIDT2), that mediates direct uptake of RNA (and DNA<sup>124</sup>) for lysosomal degradation<sup>125</sup>. At present, little is known about whether or how RNAutophagy (also known as RNaphagy) and DNAutophagy (also known as DNaphagy) affect health and aging. However, it is reasonable to suggest that nucleic acid turnover is essential for health, as accumulation of damaged or unnecessary DNA and RNA in the cytosol promotes inflammation, cancer and even accelerated aging<sup>68,126,127</sup>. DNA damage triggers autophagy and subtypes of autophagy that are considered to be cell survival responses<sup>128</sup>; in contrast, genetic or age-dependent impairment of DNA repair leads to genomic instability, cellular dysfunction, cell death and accelerated aging<sup>68</sup>. Exogenous DNA or RNA (for example, microbial) or endogenous nuclear or mitochondrial DNA in the cytoplasm may trigger autophagy. Nuclear DNA (including extranuclear chromatin) could be aberrantly released into the cytoplasm as a result of impaired nuclear envelope integrity, nuclear envelope blebbing or nuclear export processes<sup>129</sup>, while mitochondrial DNA could leak into the cytoplasm as a result of mitochondrial damage and inefficient elimination of damaged mitochondria via mitophagy<sup>126,127</sup>.

The cyclic GMP-AMP (cGAS)–stimulator of interferon genes (STING), or RIG-I–MAVS, signaling axis detects these nucleic acid fragments to initiate an innate immune reaction, linking it to autoimmunity, inflammation, senescence and autophagy<sup>129</sup>. Collectively, genomic instability, accumulation of mitochondrial DNA leakage in the cytoplasm and increased levels of cellular stress granules are linked to inflammation, accelerated aging and a broad range of neurodegenerative diseases<sup>120,121,126</sup>. Although maintenance of DNA and RNA homeostasis is critical for healthy aging, the contribution of RNAutophagy and DNAutophagy to long-term tissue health and pathology requires further exploration.

**Autophagy of subcellular organelles: mitophagy, ER-phagy, nucleophagy and lysophagy.** Aging is associated with an accumulation of damage to subcellular organelles. Timely and efficient disposal and recycling of dysfunctional organelles is necessary to maintain cellular function and viability. Selective autophagy is the common mechanism underlying the clearance of damaged and/or superfluous subcellular organelles such as mitochondria (mitophagy), the ER (reticulophagy or ER-phagy), the nucleus (nucleophagy) and lysosomes (lysophagy)<sup>17</sup>. Both membrane-bound and soluble selective autophagy receptors are involved in the selective degradation of organelles<sup>18,130</sup>.

Among the different types of autophagy targeting subcellular organelles, the most investigated is mitophagy. Mitophagy is the selective autophagic elimination of defective or surplus mitochondria. The PINK1- and parkin-mediated pathway for degradation of heavily depolarized mitochondria is best understood and involves attraction by Ser65-phosphorylated ubiquitin of the soluble selective autophagy receptors NDP52, optineurin and p62, which then recruit the core autophagy machinery for autophagosome formation on the damaged mitochondria<sup>131</sup>. Other basal, developmental and stress-induced mitophagy pathways involve binding of LC3 to a series of LIR-containing mitochondrial outer membrane proteins, such as NIX (BNIP3L), BNIP3, FKBP8, FUNDC1, BCL2L13, PHB2 and AMBRA1, as well as LC3-binding mitochondrial lipids such as cardiolipin<sup>37</sup> (Fig. 1a, pathway (6), left). While whole mitochondria can be degraded via mitophagy, it appears that organelles with minor damage can be ‘repaired’ by other quality-control mechanisms such as the piecemeal mitophagy pathway, which is a basal housekeeping mitophagy pathway that involves degradation of mitochondrial proteins in an LC3C- and p62-dependent manner<sup>132</sup> (Fig. 1a, pathway (6), right). Other mitochondrial degradation pathways include the mitochondria-derived vesicle (MDV) pathway, where damaged cargo (for example, impaired mitochondrial proteins) is delivered to the lysosome for degradation in a process dependent on syntaxin-17, PINK1 and parkin<sup>133</sup>. A recent study in *C. elegans* showed that damaged subcellular components, including mitochondria, can be budded off from certain neurons via membrane-bound vesicles (termed ‘exophers’)<sup>134</sup>. Once in the extracellular space, these damaged organelles can be engulfed and digested by surrounding cells<sup>134</sup>. This cellular release of exophers is conserved in mammals, as cardiomyocytes release exophers (containing mitochondria) to be received and eliminated by adjacent macrophages<sup>135</sup>.

Accumulating evidence has highlighted that mitophagy is a critical contributor to cellular physiology and organ homeostasis. First, there is an increase in mitophagy from juvenile stages to adulthood, followed by a dramatic reduction in aged animals. For example, there is an increase in basal mitophagy levels in fly flight muscles from the ages of 1 week to 4 weeks<sup>136</sup>; in mice, mitophagy in the dentate gyrus (DG), a region of the brain that is essential for memory, was reduced by approximately 70% between the ages of 3 and 21 months<sup>137</sup>. Mitophagy is also impaired under high-fat feeding conditions<sup>137</sup> and in neurodegenerative diseases (reviewed in ref. <sup>37</sup>). Indeed, mitophagy is reduced in mice with AD (by approximately 50% in the hippocampus in comparison to healthy controls)<sup>138</sup>,



Parkinson's disease (reviewed in ref. <sup>139</sup>) and Huntington's disease (by over 70% in the DG of huntingtin-expressing mice versus wild-type controls)<sup>137</sup>. Second, intact mitophagic machinery is required for longevity. Because there are several redundant mitophagy pathways, dysfunction of isolated individual mitophagy pathways may not affect lifespan<sup>140,141</sup>. However, mitophagy is essential for longevity under conditions of low insulin/IGF-1 signaling (*C. elegans daf-2* mutants) and dietary restriction (*C. elegans eat-2* mutants)<sup>140,142</sup>, as well as for the maintenance of neuronal functions in response to stressful conditions<sup>126</sup>. Third, mitophagy induction is sufficient to improve healthspan and extends lifespan in several model organisms, rescues age-associated neurodegenerative phenotypes in AD<sup>138,143</sup> and prolongs lifespan in nematode and fly models of accelerated aging<sup>66,111,144</sup>. Moreover, functional mitophagy is essential for restraining innate immunity, as mitochondrial stress can lead to the release of damage-associated molecular patterns (DAMPs) that activate innate immunity. Inflammation resulting from excessive exercise in *Pink1*- and *Parkin*-knockout mice has been shown to be suppressed by loss of STING, a central regulator of the type I interferon response to cytosolic DNA<sup>126</sup>.

Other autophagic pathways that target subcellular organelles include ER-phagy, nucleophagy and lysophagy. In yeast, Atg39 regulates perinuclear ER-phagy and nucleophagy, while Atg40 is necessary for cortical and cytoplasmic ER-phagy<sup>145</sup> (Fig. 1a, pathway (7)). ER-phagy is conserved in mammalian cells through specific ER-phagy receptors, such as FAM134B, SEC62, RTN3L, CCPG1, ATL3 and TEX264 (reviewed in ref. <sup>146</sup>). Nucleophagy is conserved in mammalian cells<sup>147</sup> and involves nuclear LC3B-lamin B1 interaction-based nuclear-to-cytoplasmic degradation, which may be a defense mechanism protecting cells from tumorigenesis<sup>148</sup> (Fig. 1a, pathway (8)). Lysophagy is regulated by both ubiquitin-dependent (galectin-3-TRIM16-ULK1-autophagy receptor-LC3, the F-box protein FBXO27 and UBE2QL1) and ubiquitin-independent (galectin-8-autophagy receptor-LC3) pathways (reviewed in ref. <sup>149</sup>) (Fig. 1a, pathway (11)). Maintenance of functional and effective lysosomes, via timely and efficient lysophagy, is essential for cell survival. In particular, dysfunction in lysosomal membrane proteins such as SCAV-3, the *C. elegans* homolog of human LIMP-2, has been linked to reduced lifespan, implicating lysosome integrity as a defining factor in longevity<sup>150,151,25</sup>. Moreover, dysfunctional lysosomal membrane proteins coupled to leakage of proteolytic enzymes (that is, cathepsin D) into the cytosol have been associated with aging and pathological aging in a broad range of neurodegenerative diseases<sup>152</sup>. Thus, maintaining physiological lysophagy is critical for many cellular processes and is presumably important for health and longevity, as lysosomal rupture triggers endolysosomal damage responses and even lysosomal cell death, which is linked to aging and diseases<sup>152,153</sup>.

Collectively, an imbalanced quality surveillance system for subcellular organelles, such as mitochondria, the ER, small nuclear fractions and lysosomes, might be a causative factor for age-related pathologies as well as premature aging. Further studies on mitophagy, ER-phagy, nucleophagy and lysophagy to decipher their multilayer regulatory network and association with aging and health are necessary. In particular, studies to address how these processes change with age and how they influence age-related tissue function will lead to critical insights with broad relevance to human health and quality of life.

**Xenophagy.** Xenophagy (from the Greek meaning 'to eat foreign matter') is the process by which autophagy targets pathogens<sup>154</sup>. Many pathogens are known to be degraded by autophagy, while others take over core autophagy components for their own benefit<sup>155</sup> (Fig. 1a, pathway (9)). Indeed, several studies have demonstrated that autophagy can target bacteria such as *Rickettsia conorii*<sup>156</sup>, *Listeria monocytogenes*<sup>157</sup>, *Streptococcus pyogenes*<sup>158</sup> and *Mycobacterium tuberculosis*<sup>159,160</sup>. Xenophagy may also protect the body against invasion by viruses and parasites.


Upon their intake by inhalation, *M. tuberculosis* bacteria are captured by alveolar macrophages. However, they have evolved the ability to impair phagosome maturation (which under normal conditions would lead to phagocytosis) and end up hijacking macrophages<sup>161</sup>. Later on, using secretions from ESX-1 (6-kDa early secretory antigenic target (ESAT-6) secretion system 1), the bacteria are able to break free from the phagosome and enter the cytosol. Here xenophagy comes into action. cGAS detects the bacterial DNA<sup>162</sup>, which results in ubiquitination of the invading bacteria by Smurf1 (or parkin)<sup>163</sup>. NBR1 (or p62) attaches to these ubiquitin chains, resulting in the recruitment of LC3B and, ultimately, autophagic degradation<sup>164</sup>. Indeed, an absence of autophagic machinery components, in particular, ULK1 (ref. <sup>165</sup>), BECN1 (ref. <sup>166</sup>), p62 (ref. <sup>167</sup>), ATG7 (ref. <sup>168</sup>) and TBK1 (ref. <sup>167</sup>), may promote proliferation of the bacteria. The mechanism is similar for specific viruses. BECN1 and p62 in selective autophagy of viral capsids can be protective against Sindbis virus<sup>169,170</sup>. However, other viruses, such as herpes simplex virus type 1, have evolved to inhibit autophagy by targeting BECN1 (ref. <sup>171</sup>). In addition, several studies have highlighted the importance and possible therapeutic relevance of autophagy for controlling severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19)<sup>172-174</sup>. With respect to parasites, autophagy can control *Toxoplasma gondii*, while knockout of ATG5, ATG7 or ATG16L1 renders mice more likely to succumb to parasites<sup>175</sup>. A detailed review of the relationship between parasites and autophagy is available<sup>176</sup>.

Although there are not many data available on a direct link between xenophagy and aging or lifespan, it is conceivable that blocking infection by exogenous intruders is required for maintenance of a healthy state and reduced inflammation<sup>151,177</sup>. Further work to investigate the molecular mechanisms of xenophagy and their association with aging and longevity is required.

**Tissue-specific autophagy in aging.** As aging is associated with functional decline at both the tissue and organismal level, it is important to understand how aging within individual tissues affects, and is affected by, aging across the entire organism. Evidence from nematodes, flies and mice has revealed that autophagy may have tissue-specific roles in regulating aging<sup>14</sup>. Inhibition of *lgg-1* and *atg-18* specifically in the body wall muscle of adult worms is sufficient to shorten the lifespan of the long-lived dietary-restricted *eat-2* and insulin/IGF-1 receptor-deficient *daf-2* mutants<sup>28,178</sup>. In addition, the shortened lifespan in *atg-18* mutants (ATG-18 is a member of the WIPI protein family, homologous to mammalian WIPI-1 and WIPI-2) can be suppressed by tissue-specific restoration of ATG-18 function: pan-neuronal or intestine-specific expression of *atg-18* fully restored the lifespan of *atg-18* mutants to that of wild-type worms, while muscle- or hypodermis-specific rescue of ATG-18 had little to no ability to restore lifespan<sup>179</sup>. In flies, promotion of autophagy in muscle tissue via overexpression of Atg8a or the transcription factor FOXO was sufficient to extend lifespan<sup>78,180</sup>, while, in mice, inhibition of autophagy through muscle-specific ATG7 deficiency resulted in impaired muscle function (possibly via mitochondrial dysfunction) and decreased lifespan<sup>181</sup>. Furthermore, enhancing autophagy specifically in the intestine results in maintenance of intestinal barrier function and promotes longevity and healthspan in worms and flies<sup>45,178</sup>. Given that tissues age unevenly, with some tissues presenting with faster degeneration than others<sup>182</sup>, it will be interesting to determine how closely rates of aging and autophagy are correlated in different tissues throughout life.

### Defective autophagy in diseases associated with accelerated aging, neurodegenerative diseases and inflammaging

Accumulating evidence from studies using laboratory animals and human samples supports an essential role for autophagy in



**Fig. 3 | Autophagy in health and disease.** **a**, Autophagy participates in multiple processes that are essential for longevity. **b**, A brief summary of some of the major known mechanisms that regulate autophagy in multiple organisms and their influence on the process. **c**, A list summarizing premature aging diseases with impaired mitophagy as a cause of mitochondrial dysfunction, which contributes to short lifespan (LS) and healthspan (HS). These premature aging diseases are ataxia telangiectasia (AT), Cockayne syndrome (CS), Fanconi anemia (FA), Hutchinson–Gilford syndrome (HG), Werner syndrome (WS) and xeroderma pigmentosum (XP; especially group A). Changes in autophagy and mitophagy in Hutchinson–Gilford syndrome are elusive. **d**, Autophagy (including subtypes of selective autophagy, such as mitophagy) is impaired in broad neurodegenerative diseases, where impairment may drive or exacerbate disease progression. These diseases include AD, Parkinson’s disease (PD), Huntington’s disease, ALS and frontotemporal dementia (FTD). We emphasize that these are not the only drivers of the diseases and other processes may have roles leading to pathology and symptomatology.

embryonic development, tissue health and lifespan through the suppression of age-associated inflammation (inflammaging), maintenance of genomic integrity, preservation of cellular and tissue homeostasis, and rejuvenation of stem cells (Fig. 3a; refs. <sup>13,14,68,69</sup>). While autophagy is tightly regulated by multiple molecular pathways involving central modulators of energy metabolism, such as AMPK, mTORC1, sirtuins and calcineurin (Fig. 3b), several interventions such as dietary restriction, exercise and supplementation with small chemical compounds (detailed below) stimulate autophagy<sup>69</sup>. Recent preclinical studies have linked impairment of general autophagy or subtypes of autophagy (in some diseases, while a subtype of selective autophagy is impaired, there may be no change,

or even an increase, in general autophagy) to pathological states such as progeria and a series of accelerated aging diseases<sup>68</sup> (Fig. 3c), neurodegenerative diseases<sup>13,37</sup> (Fig. 3d) and other disorders<sup>13,14,68,69</sup>. For example, maintenance of CMA in aged cells sustains HSC function<sup>183</sup> and prevents collapse of the neuronal metastable proteome<sup>184</sup>. Similarly, mitophagy, which is reduced in both normal aging and AD, extends healthspan<sup>140</sup> and suppresses amyloid β- and phosphorylated tau-induced memory loss when stimulated in aged tissues<sup>138</sup>.

Understanding the relationship between compromised autophagy and other hallmarks of aging will provide a better understanding of the molecular events that promote aging and disease<sup>14,68,69</sup>.

Among the many age-related changes previously described, inflammation is linked to autophagy, as impaired autophagy results in inflammation, and has emerged as a major driver of age-related tissue damage<sup>63,69,185,186</sup>. Inflammation is an evolutionarily conserved protective mechanism designed to maintain organismal homeostasis in the face of acute and local perturbations and serves as an adaptive response to infection or injury<sup>187</sup>. Chronic, systemic inflammation develops progressively with age and contributes to organismal deterioration through the process termed inflammaging<sup>186</sup>.

Autophagy has been identified as one of the pivotal mechanisms orchestrating the differentiation and metabolic state of innate immune cells. In particular, the balance between mTOR and AMPK activation has a central role in immune cell maintenance and function. Upon mTOR activation, autophagic flux is reduced, accompanied by increased cellular glycolytic activity, giving rise to a proliferative and pro-inflammatory phenotype in macrophages. In contrast, AMPK activation drives autophagy and promotes the OXPPOS-dependent function of non- or anti-inflammatory macrophages<sup>188</sup>.

Autophagy also regulates the NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome, which is an intracellular protein complex that activates caspase-1, which in turn catalyzes the cleavage, activation and subsequent release of pro-inflammatory cytokines (for example, interleukin (IL)-1 $\beta$ ), which can induce neurodegeneration<sup>186,189</sup>. The NLRP3 inflammasome has been identified as a critical component of the innate immune response (that is, the response to microbial motifs, endogenous danger signals and environmental irritants) and orchestrates host immune homeostasis<sup>189</sup>. Defective autophagy, for example, in models of selective knockout or knockdown of genes encoding components of the autophagic core machinery (for example, ATG5, ATG7, BECN1 and MAPI1C3B), results in unrestricted inflammasome activation and consequent inflammation. Likewise, promotion of autophagy through starvation or with pharmacological agents (for example, rapamycin) inhibits the inflammasome<sup>190</sup>. In addition, evidence stemming from an APP/PS1 mouse model of AD demonstrated mitophagy-induced inhibition of the NLRP3 inflammasome, resulting in reduced neuroinflammation<sup>138</sup>. These findings imply an important role for autophagy in the regulation of inflammation and, in turn, aging and neurodegenerative diseases.

### Anti-aging effects of autophagy modulators


The mounting evidence that an imbalance of autophagy is an important age-associated characteristic has driven extensive research into the development of compounds that can promote autophagy<sup>1</sup>. Pharmacological agents promoting autophagy can be classified on the basis of their effect on the mTOR pathway<sup>191</sup>. mTOR inhibition by rapamycin has been shown to reduce protein synthesis and promote autophagy, both of which contribute to extended lifespan in yeast, nematodes, flies and mice (Table 2). In addition, rapamycin has been demonstrated to protect against neurodegenerative diseases, including AD, via promotion of autophagy; however, rapamycin treatment was observed to be detrimental in the case of models of ALS, possibly owing to non-autophagy-related side effects<sup>191</sup>. Other pharmacological agents reported to promote autophagy via direct interaction with mTOR include torin-1 and PP242 (ref. 192). mTOR-independent promoters of autophagy mainly act via the AMPK pathway. Examples include metformin and trehalose, which have been demonstrated to be effective in enhancing autophagy, extending lifespan and protecting against neurodegeneration in experimental models<sup>191</sup>.

Compounds such as resveratrol and spermidine modulate the acetylation state of proteins to regulate autophagy and promote longevity. Resveratrol is a natural polyphenol that reportedly promotes lifespan in *C. elegans* and healthspan in mice via activation of the NAD<sup>+</sup>-dependent deacetylase SIRT1 (refs. 112,193,194). Spermidine is a polyamine that extends the lifespan of yeast, worms, flies and

mice by enhancing autophagy through inhibition of the EP300 acetyltransferase<sup>195</sup>, among other mechanisms<sup>55,196–198</sup>. The longevity-extending effects of spermidine are abolished upon depletion or deletion of essential autophagy genes such as *bec-1* in *C. elegans* and *Atg7* in yeast and flies<sup>197,199</sup>. Furthermore, pharmacological inhibition of XPO-1 results in enhanced autophagy (as evidenced by an increase in the frequency of autophagosomes and autolysosomes) and increased lifespan in *C. elegans*. These effects were mediated by nuclear enrichment of HLH-30, which occurred in an mTOR-independent manner<sup>47</sup>. Additional modulators of TFEB homologs that regulate autophagy and have also been demonstrated to protect against pathophysiological aging include ouabain and fisetin. Ouabain is a cardiac glycoside that enhances activation of TFEB through inhibition of the mTOR pathway and induces downstream autophagy-lysosomal gene expression and cellular restorative properties<sup>200</sup>. Ouabain has been shown to reduce the accumulation of abnormal toxic tau both in vitro and in vivo<sup>200</sup>. Fisetin is a flavonol and was shown to facilitate the clearance of endogenous tau via TFEB (through inhibition of mTOR kinases) and Nrf2 activation<sup>20</sup>.

Other small molecules that induce subtypes of autophagy, especially mitophagy, also enhance longevity and suppress age-associated diseases. These include NAD<sup>+</sup>, a fundamental metabolite in energy metabolism, redox homeostasis, mitochondrial function, and the arbitration of cell survival and death<sup>185</sup>. NAD<sup>+</sup>-activated sirtuins stimulate autophagy via mTOR inhibition and deacetylation of several key autophagy proteins (ATG5, ATG7 and ATG8)<sup>201,202</sup>. In addition, the NAD<sup>+</sup>-SIRT axis activates mitophagy by increasing the activity of a series of mitophagy-related proteins, such as PINK1, parkin, NIX (DCT-1 in *C. elegans*) and BNIP3 (refs. 66,203). Supplementation with NAD<sup>+</sup> precursors, such as nicotinamide (NAM), nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), can increase lifespan and/or improve healthspan in worms, flies and mice<sup>111,204–206</sup>. NAD<sup>+</sup> augmentation also prevents memory loss in both amyloid  $\beta$  and tau *C. elegans* and mouse models of AD, in a mitophagy-dependent manner (requiring *pink-1*, *pdr-1* or *dct-1*)<sup>138</sup>. Over seven human clinical trials have shown the safety and bioavailability of NR (1–2 g per day for up to 3 months); there are more than 30 ongoing clinical trials on the use of NR to treat premature aging and other age-related diseases (see a review in ref. 185). Another clinically promising mitophagy inducer is urolithin A, a metabolite of ellagitannins from the gut microflora. Urolithin A extends healthspan and lifespan in *C. elegans*, with lifespan extension depending on genes involved in autophagy (that is, *bec-1*, *sqst-1* and *vps-34*) and mitophagy (*pink-1*, *dct-1* and the nonspecific *skn-1*)<sup>207</sup>. Intriguingly, urolithin A inhibits memory loss in both amyloid  $\beta$  and tau *C. elegans* and mouse models of AD in a mitophagy-dependent manner (dependent on *pink-1*, *pdr-1* or *dct-1*)<sup>138</sup>. Urolithin A (500 mg and 1,000 mg per day for 4 weeks) was also shown to be safe in a phase 1 clinical trial<sup>208</sup>. A summary of different lifespan/health-benefit mitophagy inducers can be found in Table 2. Encouraged by the clinical safety of NR and urolithin A, their effects on healthspan and lifespan in older individuals deserve further investigation. Despite recent progress in the identification of novel as well as well-known autophagy-inducing compounds, it is also of great importance to highlight the pleiotropic effects of these pharmacological interventions and to completely understand the full complement of targets with which they interact to use them safely for therapeutic intervention.

While experimental/empirical evidence indicates that autophagy is defective in older individuals, it is conceivable that exposing individuals to autophagy inducers, dietary restriction and exercise late in life could boost autophagy and result in benefits to tissue function<sup>209,210</sup> (Fig. 4a). On the basis of preclinical data, it is presumed that autophagy stimulation (ideally to increase autophagy to the levels observed early in adulthood) may be sufficient to provide benefits (Fig. 4b).



**Fig. 4 | Maintaining autophagy through lifestyle and medical interventions prolongs longevity.** **a**, Potential interventions to stimulate autophagy: autophagy inducers, dietary restriction, exercise and genetic approaches. **b**, Autophagy induction could positively impact human health.

### Conclusions and future perspectives

Mounting evidence from studies using laboratory animals, human tissues and related clinical trials supports the concept that (1) there is an age-dependent decline in autophagy, (2) autophagy is a crucial determinant of cellular health and organismal longevity and (3) impairment or imbalance in autophagy promotes pathological aging and disease. Given the broad spectrum of unique properties associated with autophagy, we propose that ‘compromised autophagy’ is a central feature of normal aging. Although the relationship between autophagy and aging is often described as ‘decreased autophagy is detrimental’ and ‘increased autophagy is beneficial’, this may be too simplistic a picture. Instead, long-term health benefits will likely arise from achieving the right balance of autophagy, which itself will depend on tissue and organismal age. For example, in *C. elegans*, impairing autophagy early in life has a negative effect on longevity, whereas knockdown of a specific subset of autophagy genes in adulthood may have beneficial effects on lifespan<sup>59</sup>. Similarly, increased autophagy through a hypermorphic allele of *atg-5* has differential effects on polyglutamine aggregation in the muscles and neurons of *C. elegans*<sup>211</sup>. In flies, a mild increase in autophagy extends lifespan, whereas strongly increasing autophagy shortens lifespan<sup>212</sup>. It should also be noted that autophagy induction may also result in unwanted effects, such as multiple senescence pathologies<sup>59</sup> and resistance to cancer therapy (reviewed in ref. <sup>213</sup>). Collectively, these observations suggest that the level of and balance among the different forms of autophagy in each tissue are highly specified for each stage of life, and an understanding of this will be crucial for healthy aging. Thus, while different types of autophagy may influence aging to different extents, a central goal for promoting health will be to find approaches that can fine-tune autophagy to the right levels, at the right time and in the right tissues, to enhance health (Fig. 4). To achieve this, it will be critical to develop novel interventions that allow for controlled delivery of autophagy modulators into specific tissues or cell types at precise stages of life. Such therapeutic strategies could then be administered chronically, acutely or in a pulsed fashion as and when required. Additionally, it may be necessary to specifically induce either general or selective autophagy to provide overall long-term health benefits<sup>66</sup>. For example, premature aging diseases such as ataxia telangiectasia, xeroderma pigmentosum group A and Cockayne syndrome exhibit increased general autophagy but impaired mitophagy; therefore, specifically stimulating

mitophagy, rather than general autophagy, would be the most efficient way to counteract pathological features while avoiding detrimental side effects<sup>66</sup>.

There are many outstanding questions related to autophagy in aging that need to be addressed. For example, what are the intricate mechanisms that orchestrate distinct autophagic pathways? How is autophagy spatially and temporally regulated, and how does disruption of this regulation suppress or promote disease? Are some aspects of autophagy more important in an age- and/or tissue-dependent manner? What are the determining factors that dictate the route of degradation, via the UPS or autophagy? How are clearance mechanisms balanced with synthesis and folding through the proteostasis network? What are the thresholds of life-beneficial and life-detrimental autophagy? In line with the traditional Chinese yin–yang philosophy, autophagy must be balanced, as diminished autophagy results in the accumulation of toxic subcellular components while excessive autophagy can lead to organ atrophy and other detrimental effects<sup>14,37,59,69,212</sup>. Furthermore, compensatory responses between proteolytic systems (for example, between autophagy and the UPS<sup>214</sup>) have a critical role in determining the onset and rate of age-related tissue deterioration and should be considered in future experimental designs and data interpretation. Finally, are there any conditions or diseases where we should be cautious about inducing autophagy, in that protection against one form of pathology may increase the risk for another? For example, pancreatic cancer cells may hijack autophagy processes to obtain nutrients for growth; hence, in this condition, autophagy inhibition in combination with cancer chemotherapies may inhibit pancreatic cancer growth<sup>215,216</sup>. Addressing these questions will facilitate understanding of the aging process and, more importantly, enable identification of novel targets that may be manipulated for therapeutic intervention in age-associated diseases.

Received: 16 February 2021; Accepted: 7 July 2021;  
Published online: 12 August 2021

### References

- Leidal, A. M., Levine, B. & Debnath, J. Autophagy and the cell biology of age-related disease. *Nat. Cell Biol.* **20**, 1338–1348 (2018).
- Partridge, L., Deelen, J. & Slagboom, P. E. Facing up to the global challenges of ageing. *Nature* **561**, 45–56 (2018).

3. Fang, E. F. et al. A research agenda for ageing in China in the 21st century (2nd edition): focusing on basic and translational research, long-term care, policy and social networks. *Ageing Res. Rev.* **64**, 101174 (2020).
4. Dikic, I. & Elazar, Z. Mechanism and medical implications of mammalian autophagy. *Nat. Rev. Mol. Cell Biol.* **19**, 349–364 (2018).
5. Ashford, T. P. & Porter, K. R. Cytoplasmic components in hepatic cell lysosomes. *J. Cell Biol.* **12**, 198–202 (1962).
6. Deter, R. L. & De Duve, C. Influence of glucagon, an inducer of cellular autophagy, on some physical properties of rat liver lysosomes. *J. Cell Biol.* **33**, 437–449 (1967).
7. Klionsky, D. J. Autophagy revisited: a conversation with Christian de Duve. *Autophagy* **4**, 740–743 (2008).
8. Tsukada, M. & Ohsumi, Y. Isolation and characterization of autophagy-defective mutants of *Saccharomyces cerevisiae*. *FEBS Lett.* **333**, 169–174 (1993).
9. Harding, T. M., Morano, K. A., Scott, S. V. & Klionsky, D. J. Isolation and characterization of yeast mutants in the cytoplasm to vacuole protein targeting pathway. *J. Cell Biol.* **131**, 591–602 (1995).
10. Thumm, M. et al. Isolation of autophagocytosis mutants of *Saccharomyces cerevisiae*. *FEBS Lett.* **349**, 275–280 (1994).
11. Schlumberger, M. et al. *AUT1*, a gene essential for autophagocytosis in the yeast *Saccharomyces cerevisiae*. *J. Bacteriol.* **179**, 1068–1076 (1997).
12. Straub, M., Bredschneider, M. & Thumm, M. *AUT3*, a serine/threonine kinase gene, is essential for autophagocytosis in *Saccharomyces cerevisiae*. *J. Bacteriol.* **179**, 3875–3883 (1997).
13. Kaushik, S. & Cuervo, A. M. The coming of age of chaperone-mediated autophagy. *Nat. Rev. Mol. Cell Biol.* **19**, 365–381 (2018).
14. Hansen, M., Rubinsztein, D. C. & Walker, D. W. Autophagy as a promoter of longevity: insights from model organisms. *Nat. Rev. Mol. Cell Biol.* **19**, 579–593 (2018).
15. Bjorkoy, G. et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. *J. Cell Biol.* **171**, 603–614 (2005).
16. Pankiv, S. et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. *J. Biol. Chem.* **282**, 24131–24145 (2007).
17. Kirkin, V. History of the selective autophagy research: how did it begin and where does it stand today? *J. Mol. Biol.* **432**, 3–27 (2020).
18. Gatica, D., Lahiri, V. & Klionsky, D. J. Cargo recognition and degradation by selective autophagy. *Nat. Cell Biol.* **20**, 233–242 (2018).
19. Menzies, F. M., Fleming, A. & Rubinsztein, D. C. Compromised autophagy and neurodegenerative diseases. *Nat. Rev. Neurosci.* **16**, 345–357 (2015).
20. Kim, S. et al. Fisetin stimulates autophagic degradation of phosphorylated tau via the activation of TFEB and Nrf2 transcription factors. *Sci. Rep.* **6**, 24933 (2016).
21. Medina, D. L. et al. Lysosomal calcium signalling regulates autophagy through calcineurin and TFEB. *Nat. Cell Biol.* **17**, 288–299 (2015).
22. Settembre, C. et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. *EMBO J.* **31**, 1095–1108 (2012).
23. El-Houjeiri, L. et al. The transcription factors TFEB and TFE3 link the FLCN–AMPK signaling axis to innate immune response and pathogen resistance. *Cell Rep.* **26**, 3613–3628 (2019).
24. Cuervo, A. M. & Dice, J. F. How do intracellular proteolytic systems change with age? *Front. Biosci.* **3**, D25–D43 (1998).
25. Sun, Y. et al. Lysosome activity is modulated by multiple longevity pathways and is important for lifespan extension in *C. elegans*. *eLife* <https://doi.org/10.7554/eLife.55745> (2020).
26. Sarkis, G. J., Ashcom, J. D., Hawdon, J. M. & Jacobson, L. A. Decline in protease activities with age in the nematode *Caenorhabditis elegans*. *Mech. Ageing Dev.* **45**, 191–201 (1988).
27. Hughes, A. L. & Gottschling, D. E. An early age increase in vacuolar pH limits mitochondrial function and lifespan in yeast. *Nature* **492**, 261–265 (2012).
28. Chang, J. T., Kumsta, C., Hellman, A. B., Adams, L. M. & Hansen, M. Spatiotemporal regulation of autophagy during *Caenorhabditis elegans* aging. *eLife* <https://doi.org/10.7554/eLife.18459> (2017).
29. Wilhelm, T. et al. Neuronal inhibition of the autophagy nucleation complex extends life span in post-reproductive *C. elegans*. *Genes Dev.* **31**, 1561–1572 (2017).
30. Simonsen, A. et al. Promoting basal levels of autophagy in the nervous system enhances longevity and oxidant resistance in adult *Drosophila*. *Autophagy* **4**, 176–184 (2008).
31. Kaushik, S. et al. Loss of autophagy in hypothalamic POMC neurons impairs lipolysis. *EMBO Rep.* **13**, 258–265 (2012).
32. Ott, C., Konig, J., Hohn, A., Jung, T. & Grune, T. Macroautophagy is impaired in old murine brain tissue as well as in senescent human fibroblasts. *Redox Biol.* **10**, 266–273 (2016).
33. Triplett, J. C. et al. Age-related changes in the proteostasis network in the brain of the naked mole-rat: implications promoting healthy longevity. *Biochim. Biophys. Acta* **1852**, 2213–2224 (2015).
34. Yu, Y. et al. The alteration of autophagy and apoptosis in the hippocampus of rats with natural aging-dependent cognitive deficits. *Behav. Brain Res.* **334**, 155–162 (2017).
35. Lipinski, M. M. et al. Genome-wide analysis reveals mechanisms modulating autophagy in normal brain aging and in Alzheimer's disease. *Proc. Natl Acad. Sci. USA* **107**, 14164–14169 (2010).
36. Cheon, S. Y., Kim, H., Rubinsztein, D. C. & Lee, J. E. Autophagy, cellular aging and age-related human diseases. *Exp. Neurobiol.* **28**, 643–657 (2019).
37. Lou, G. et al. Mitophagy and neuroprotection. *Trends Mol. Med.* <https://doi.org/10.1016/j.molmed.2019.07.002> (2019).
38. Maticic, M. et al. A microarray-based genetic screen for yeast chronological aging factors. *PLoS Genet.* **6**, e1000921 (2010).
39. Toth, M. L. et al. Longevity pathways converge on autophagy genes to regulate life span in *Caenorhabditis elegans*. *Autophagy* **4**, 330–338 (2008).
40. Kuma, A., Komatsu, M. & Mizushima, N. Autophagy-monitoring and autophagy-deficient mice. *Autophagy* **13**, 1619–1628 (2017).
41. Lin, X. X. et al. DAF-16/FOXO and HLH-30/TFEB function as combinatorial transcription factors to promote stress resistance and longevity. *Nat. Commun.* **9**, 4400 (2018).
42. Melendez, A. et al. Autophagy genes are essential for dauer development and life-span extension in *C. elegans*. *Science* **301**, 1387–1391 (2003).
43. Lapiere, L. R. et al. The TFEB orthologue HLH-30 regulates autophagy and modulates longevity in *Caenorhabditis elegans*. *Nat. Commun.* **4**, 2267 (2013).
44. Pyo, J. O. et al. Overexpression of Atg5 in mice activates autophagy and extends lifespan. *Nat. Commun.* **4**, 2300 (2013).
45. Ulgherait, M., Rana, A., Rera, M., Graniel, J. & Walker, D. W. AMPK modulates tissue and organismal aging in a non-cell-autonomous manner. *Cell Rep.* **8**, 1767–1780 (2014).
46. Fernandez, A. F. et al. Disruption of the beclin 1–BCL2 autophagy regulatory complex promotes longevity in mice. *Nature* **558**, 136–140 (2018).
47. Silvestrini, M. J. et al. Nuclear export inhibition enhances HLH-30/TFEB activity, autophagy, and lifespan. *Cell Rep.* **23**, 1915–1921 (2018).
48. Harrison, D. E. et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature* **460**, 392–395 (2009).
49. Pareja-Cajiao, M. et al. Age-related impairment of autophagy in cervical motor neurons. *Exp. Gerontol.* **144**, 111193 (2021).
50. Nettesheim, A. et al. Autophagy in the aging and experimental ocular hypertensive mouse model. *Invest. Ophthalmol. Vis. Sci.* **61**, 31 (2020).
51. Fernando, R. et al. Age-related maintenance of the autophagy–lysosomal system is dependent on skeletal muscle type. *Oxid. Med. Cell. Longev.* **2020**, 4908162 (2020).
52. Liang, W. et al. Aging is associated with a decline in Atg9b-mediated autophagosome formation and appearance of enlarged mitochondria in the heart. *Aging Cell* **19**, e13187 (2020).
53. Kamihara, T. & Murohara, T. Bioinformatics analysis of autophagy–lysosomal degradation in cardiac aging. *Geriatr. Gerontol. Int.* **21**, 108–115 (2021).
54. Fang, Y. et al. Autophagy–Sirt3 axis decelerates hematopoietic aging. *Aging Cell* **19**, e13232 (2020).
55. Alsaleh, G. et al. Autophagy in T cells from aged donors is maintained by spermidine and correlates with function and vaccine responses. *eLife* <https://doi.org/10.7554/eLife.57950> (2020).
56. De Risi, M. et al. Mechanisms by which autophagy regulates memory capacity in ageing. *Aging Cell* **19**, e13189 (2020).
57. Yamamuro, T. et al. Age-dependent loss of adipose Rubicon promotes metabolic disorders via excess autophagy. *Nat. Commun.* **11**, 4150 (2020).
58. Zhou, B. et al. Mitochondrial permeability uncouples elevated autophagy and lifespan extension. *Cell* **177**, 299–314 (2019).
59. Ezcurra, M. et al. *C. elegans* eats its own intestine to make yolk leading to multiple senescent pathologies. *Curr. Biol.* **28**, 2544–2556 (2018).
60. Lapiere, L. R. et al. Autophagy genes are required for normal lipid levels in *C. elegans*. *Autophagy* **9**, 278–286 (2013).
61. Hansen, M. et al. A role for autophagy in the extension of lifespan by dietary restriction in *C. elegans*. *PLoS Genet.* **4**, e24 (2008).
62. Labbadia, J. & Morimoto, R. I. The biology of proteostasis in aging and disease. *Annu. Rev. Biochem.* **84**, 435–464 (2015).
63. Lopez-Otin, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. The hallmarks of aging. *Cell* **153**, 1194–1217 (2013).
64. Ravikumar, B., Duden, R. & Rubinsztein, D. C. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. *Hum. Mol. Genet.* **11**, 1107–1117 (2002).
65. Ravikumar, B. et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. *Nat. Genet.* **36**, 585–595 (2004).

66. Fang, E. F. et al. Defective mitophagy in XPA via PARP-1 hyperactivation and NAD<sup>+</sup>/SIRT1 reduction. *Cell* **157**, 882–896 (2014).
67. Boland, B. et al. Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing. *Nat. Rev. Drug Discov.* **17**, 660–688 (2018).
68. Fang, E. F. et al. Nuclear DNA damage signalling to mitochondria in ageing. *Nat. Rev. Mol. Cell Biol.* **17**, 308–321 (2016).
69. Rubinsztein, D. C., Marino, G. & Kroemer, G. Autophagy and aging. *Cell* **146**, 682–695 (2011).
70. Kumsta, C., Chang, J. T., Schmalz, J. & Hansen, M. Hormetic heat stress and HSF-1 induce autophagy to improve survival and proteostasis in *C. elegans*. *Nat. Commun.* **8**, 14337 (2017).
71. Juhasz, G., Erdi, B., Sass, M. & Neufeld, T. P. Atg7-dependent autophagy promotes neuronal health, stress tolerance, and longevity but is dispensable for metamorphosis in *Drosophila*. *Genes Dev.* **21**, 3061–3066 (2007).
72. Hara, T. et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. *Nature* **441**, 885–889 (2006).
73. Komatsu, M. et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. *Nature* **441**, 880–884 (2006).
74. Friedman, L. G. et al. Disrupted autophagy leads to dopaminergic axon and dendrite degeneration and promotes presynaptic accumulation of  $\alpha$ -synuclein and LRRK2 in the brain. *J. Neurosci.* **32**, 7585–7593 (2012).
75. Schneider, J. L. et al. Loss of hepatic chaperone-mediated autophagy accelerates proteostasis failure in aging. *Aging Cell* **14**, 249–264 (2015).
76. Kumsta, C. et al. The autophagy receptor p62/SQST-1 promotes proteostasis and longevity in *C. elegans* by inducing autophagy. *Nat. Commun.* **10**, 5648 (2019).
77. Aparicio, R., Rana, A. & Walker, D. W. Upregulation of the autophagy adaptor p62/SQSTM1 prolongs health and lifespan in middle-aged *Drosophila*. *Cell Rep.* **28**, 1029–1040 (2019).
78. Demontis, F. & Perrimon, N. FOXO/4E-BP signaling in *Drosophila* muscles regulates organism-wide proteostasis during aging. *Cell* **143**, 813–825 (2010).
79. Nezis, I. P. et al. Ref(2)P, the *Drosophila melanogaster* homologue of mammalian p62, is required for the formation of protein aggregates in adult brain. *J. Cell Biol.* **180**, 1065–1071 (2008).
80. Lopez, A. et al. A152T tau allele causes neurodegeneration that can be ameliorated in a zebrafish model by autophagy induction. *Brain* **140**, 1128–1146 (2017).
81. Rocchi, A. et al. A *Becn1* mutation mediates hyperactive autophagic sequestration of amyloid oligomers and improved cognition in Alzheimer's disease. *PLoS Genet.* **13**, e1006962 (2017).
82. Fu, H. et al. A tau homeostasis signature is linked with the cellular and regional vulnerability of excitatory neurons to tau pathology. *Nat. Neurosci.* **22**, 47–56 (2019).
83. Schinaman, J. M., Rana, A., Ja, W. W., Clark, R. I. & Walker, D. W. Rapamycin modulates tissue aging and lifespan independently of the gut microbiota in *Drosophila*. *Sci. Rep.* **9**, 7824 (2019).
84. Berger, Z. et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. *Hum. Mol. Genet.* **15**, 433–442 (2006).
85. Audesse, A. J. et al. FOXO3 directly regulates an autophagy network to functionally regulate proteostasis in adult neural stem cells. *PLoS Genet.* **15**, e1008097 (2019).
86. Leeman, D. S. et al. Lysosome activation clears aggregates and enhances quiescent neural stem cell activation during aging. *Science* **359**, 1277–1283 (2018).
87. Garcia-Prat, L. et al. Autophagy maintains stemness by preventing senescence. *Nature* **529**, 37–42 (2016).
88. Kuma, A. et al. The role of autophagy during the early neonatal starvation period. *Nature* **432**, 1032–1036 (2004).
89. Yang, Z., Huang, J., Geng, J., Nair, U. & Klionsky, D. J. Atg22 recycles amino acids to link the degradative and recycling functions of autophagy. *Mol. Biol. Cell* **17**, 5094–5104 (2006).
90. Suzuki, S. W., Onodera, J. & Ohsumi, Y. Starvation induced cell death in autophagy-defective yeast mutants is caused by mitochondria dysfunction. *PLoS ONE* **6**, e17412 (2011).
91. Ha, J., Guan, K. L. & Kim, J. AMPK and autophagy in glucose/glycogen metabolism. *Mol. Aspects Med.* **46**, 46–62 (2015).
92. Adeva-Andany, M. M., Gonzalez-Lucan, M., Donapetry-Garcia, C., Fernandez-Fernandez, C. & Ameneiros-Rodriguez, E. Glycogen metabolism in humans. *BBA Clin.* **5**, 85–100 (2016).
93. Yao, W. et al. Atg11 is required for initiation of glucose starvation-induced autophagy. *Autophagy* <https://doi.org/10.1080/15548627.2020.1719724> (2020).
94. Jiang, S., Wells, C. D. & Roach, P. J. Starch-binding domain-containing protein 1 (Stbd1) and glycogen metabolism: identification of the Atg8 family interacting motif (AIM) in Stbd1 required for interaction with GABARAPL1. *Biochem. Biophys. Res. Commun.* **413**, 420–425 (2011).
95. Weber, C. A. et al.  $\beta$ -Oxidation and autophagy are critical energy providers during acute glucose depletion in *Saccharomyces cerevisiae*. *Proc. Natl Acad. Sci. USA* **117**, 12239–12248 (2020).
96. Kim, K. A. et al. High glucose condition induces autophagy in endothelial progenitor cells contributing to angiogenic impairment. *Biol. Pharm. Bull.* **37**, 1248–1252 (2014).
97. Kishmani, P. S. et al. Pompe disease diagnosis and management guideline. *Genet. Med.* **8**, 267–288 (2006).
98. Kishnani, P. S. et al. Recombinant human acid  $\alpha$ -glucosidase: major clinical benefits in infantile-onset Pompe disease. *Neurology* **68**, 99–109 (2007).
99. Duran, J., Gruart, A., Garcia-Rocha, M., Delgado-Garcia, J. M. & Guinovart, J. J. Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease. *Hum. Mol. Genet.* **23**, 3147–3156 (2014).
100. Singh, R. et al. Autophagy regulates lipid metabolism. *Nature* **458**, 1131–1135 (2009).
101. Ward, C. et al. Autophagy, lipophagy and lysosomal lipid storage disorders. *Biochim. Biophys. Acta* **1861**, 269–284 (2016).
102. Kaushik, S. & Cuervo, A. M. Degradation of lipid droplet-associated proteins by chaperone-mediated autophagy facilitates lipolysis. *Nat. Cell Biol.* **17**, 759–770 (2015).
103. Goeritzer, M. et al. Active autophagy but not lipophagy in macrophages with defective lipolysis. *Biochim. Biophys. Acta* **1851**, 1304–1316 (2015).
104. Kiffin, R. et al. Altered dynamics of the lysosomal receptor for chaperone-mediated autophagy with age. *J. Cell Sci.* **120**, 782–791 (2007).
105. Palikaras, K. et al. Ectopic fat deposition contributes to age-associated pathology in *Caenorhabditis elegans*. *J. Lipid Res.* **58**, 72–80 (2017).
106. Stranks, A. J. et al. Autophagy controls acquisition of aging features in macrophages. *J. Innate Immun.* **7**, 375–391 (2015).
107. Lapierre, L. R., Melendez, A. & Hansen, M. Autophagy links lipid metabolism to longevity in *C. elegans*. *Autophagy* **8**, 144–146 (2012).
108. Folick, A. et al. Lysosomal signaling molecules regulate longevity in *Caenorhabditis elegans*. *Science* **347**, 83–86 (2015).
109. Lapierre, L. R., Gelino, S., Melendez, A. & Hansen, M. Autophagy and lipid metabolism coordinately modulate life span in germline-less *C. elegans*. *Curr. Biol.* **21**, 1507–1514 (2011).
110. Zhang, T. et al. SIRT3 promotes lipophagy and chaperone-mediated autophagy to protect hepatocytes against lipotoxicity. *Cell Death Differ.* **27**, 329–344 (2020).
111. Fang, E. F. et al. NAD<sup>+</sup> augmentation restores mitophagy and limits accelerated aging in Werner syndrome. *Nat. Commun.* **10**, 5284 (2019).
112. Baur, J. A. et al. Resveratrol improves health and survival of mice on a high-calorie diet. *Nature* **444**, 337–342 (2006).
113. Ding, W. X., Li, M. & Yin, X. M. Selective taste of ethanol-induced autophagy for mitochondria and lipid droplets. *Autophagy* **7**, 248–249 (2011).
114. Kounakis, K., Chaniotakis, M., Markaki, M. & Tavernarakis, N. Emerging roles of lipophagy in health and disease. *Front. Cell Dev. Biol.* **7**, 185 (2019).
115. Chao, X. et al. Impaired TFEB-mediated lysosome biogenesis and autophagy promote chronic ethanol-induced liver injury and steatosis in mice. *Gastroenterology* **155**, 865–879 (2018).
116. Hernandez-Gea, V. et al. Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. *Gastroenterology* **142**, 938–946 (2012).
117. Riffelmacher, T. et al. Autophagy-dependent generation of free fatty acids is critical for normal neutrophil differentiation. *Immunity* **47**, 466–480 (2017).
118. Kawane, K., Motani, K. & Nagata, S. DNA degradation and its defects. *Cold Spring Harb. Perspect. Biol.* <https://doi.org/10.1101/cshperspect.a016394> (2014).
119. Houseley, J. & Tollervey, D. The many pathways of RNA degradation. *Cell* **136**, 763–776 (2009).
120. Buchan, J. R., Kolaitis, R. M., Taylor, J. P. & Parker, R. Eukaryotic stress granules are cleared by autophagy and Cdc48/VCP function. *Cell* **153**, 1461–1474 (2013).
121. Guo, H. et al. Autophagy supports genomic stability by degrading retrotransposon RNA. *Nat. Commun.* **5**, 5276 (2014).
122. Fujiwara, Y. et al. Direct uptake and degradation of DNA by lysosomes. *Autophagy* **9**, 1167–1171 (2013).
123. Fujiwara, Y. et al. Discovery of a novel type of autophagy targeting RNA. *Autophagy* **9**, 403–409 (2013).
124. Aizawa, S. et al. Lysosomal membrane protein SIDT2 mediates the direct uptake of DNA by lysosomes. *Autophagy* **13**, 218–222 (2017).
125. Aizawa, S. et al. Lysosomal putative RNA transporter SIDT2 mediates direct uptake of RNA by lysosomes. *Autophagy* **12**, 565–578 (2016).
126. Sliter, D. A. et al. Parkin and PINK1 mitigate STING-induced inflammation. *Nature* **561**, 258–262 (2018).
127. West, A. P. et al. Mitochondrial DNA stress primes the antiviral innate immune response. *Nature* **520**, 553–557 (2015).

128. Dan, X. et al. DNA damage invokes mitophagy through a pathway involving Spata18. *Nucleic Acids Res.* **48**, 6611–6623 (2020).
129. Hopfner, K. P. & Hornung, V. Molecular mechanisms and cellular functions of cGAS–STING signalling. *Nat. Rev. Mol. Cell Biol.* **21**, 501–521 (2020).
130. Johansen, T. & Lamark, T. Selective autophagy: ATG8 family proteins, LIR motifs and cargo receptors. *J. Mol. Biol.* **432**, 80–103 (2020).
131. Pickles, S., Vigie, P. & Youle, R. J. Mitophagy and quality control mechanisms in mitochondrial maintenance. *Curr. Biol.* **28**, R170–R185 (2018).
132. Le Guerroue, F. et al. Autophagosomal content profiling reveals an LC3C-dependent piecemeal mitophagy pathway. *Mol. Cell* **68**, 786–796 (2017).
133. McLelland, G. L., Lee, S. A., McBride, H. M. & Fon, E. A. Syntaxin-17 delivers PINK1/parkin-dependent mitochondrial vesicles to the endolysosomal system. *J. Cell Biol.* **214**, 275–291 (2016).
134. Melentijevic, I. et al. *C. elegans* neurons jettison protein aggregates and mitochondria under neurotoxic stress. *Nature* **542**, 367–371 (2017).
135. Nicolas-Avila, J. A. et al. A network of macrophages supports mitochondrial homeostasis in the heart. *Cell* **183**, 94–109 (2020).
136. Cornelissen, T. et al. Deficiency of parkin and PINK1 impairs age-dependent mitophagy in *Drosophila*. *eLife* <https://doi.org/10.7554/eLife.35878> (2018).
137. Sun, N. et al. Measuring in vivo mitophagy. *Mol. Cell* **60**, 685–696 (2015).
138. Fang, E. F. et al. Mitophagy inhibits amyloid- $\beta$  and tau pathology and reverses cognitive deficits in models of Alzheimer's disease. *Nat. Neurosci.* **22**, 401–412 (2019).
139. Pickrell, A. M. & Youle, R. J. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. *Neuron* **85**, 257–273 (2015).
140. Palikaras, K., Lionaki, E. & Tavernarakis, N. Coordination of mitophagy and mitochondrial biogenesis during ageing in *C. elegans*. *Nature* **521**, 525–528 (2015).
141. McWilliams, T. G. et al. Basal mitophagy occurs independently of PINK1 in mouse tissues of high metabolic demand. *Cell Metab.* **27**, 439–449 (2018).
142. Fang, E. F. et al. Tomatidine enhances lifespan and healthspan in *C. elegans* through mitophagy induction via the SKN-1/Nrf2 pathway. *Sci. Rep.* **7**, 46208 (2017).
143. Du, F. et al. PINK1 signalling rescues amyloid pathology and mitochondrial dysfunction in Alzheimer's disease. *Brain* **140**, 3233–3251 (2017).
144. Fang, E. F. et al. NAD<sup>+</sup> replenishment improves lifespan and healthspan in ataxia telangiectasia models via mitophagy and DNA repair. *Cell Metab.* **24**, 566–581 (2016).
145. Mochida, K. et al. Receptor-mediated selective autophagy degrades the endoplasmic reticulum and the nucleus. *Nature* **522**, 359–362 (2015).
146. Hubner, C. A. & Dikic, I. ER-phagy and human diseases. *Cell Death Differ.* **27**, 833–842 (2020).
147. Park, Y. E. et al. Autophagic degradation of nuclear components in mammalian cells. *Autophagy* **5**, 795–804 (2009).
148. Dou, Z. et al. Autophagy mediates degradation of nuclear lamina. *Nature* **527**, 105–109 (2015).
149. Papadopoulos, C., Kravic, B. & Meyer, H. Repair or lysophagy: dealing with damaged lysosomes. *J. Mol. Biol.* **432**, 231–239 (2020).
150. Li, Y. et al. The lysosomal membrane protein SCAV-3 maintains lysosome integrity and adult longevity. *J. Cell Biol.* **215**, 167–185 (2016).
151. Vesosky, B. & Turner, J. The influence of age on immunity to infection with *Mycobacterium tuberculosis*. *Immunol. Rev.* **205**, 229–243 (2005).
152. Papadopoulos, C. & Meyer, H. Detection and clearance of damaged lysosomes by the endo-lysosomal damage response and lysophagy. *Curr. Biol.* **27**, R1330–R1341 (2017).
153. Gomez-Sintes, R., Ledesma, M. D. & Boya, P. Lysosomal cell death mechanisms in aging. *Ageing Res. Rev.* **32**, 150–168 (2016).
154. Reggion, A., Buonomo, V. & Grumati, P. Eating the unknown: xenophagy and ER-phagy are cytoprotective defenses against pathogens. *Exp. Cell. Res.* **396**, 112276 (2020).
155. Levine, B. Eating oneself and uninvited guests: autophagy-related pathways in cell defense. *Cell* **120**, 159–162 (2005).
156. Rikhihisa, Y. Glycogen autophagosomes in polymorphonuclear leukocytes induced by rickettsiae. *Anat. Rec.* **208**, 319–327 (1984).
157. Rich, K. A., Burkett, C. & Webster, P. Cytoplasmic bacteria can be targets for autophagy. *Cell. Microbiol.* **5**, 455–468 (2003).
158. Nakagawa, I. et al. Autophagy defends cells against invading group A *Streptococcus*. *Science* **306**, 1037–1040 (2004).
159. Gutierrez, M. G. et al. Autophagy is a defense mechanism inhibiting BCG and *Mycobacterium tuberculosis* survival in infected macrophages. *Cell* **119**, 753–766 (2004).
160. Kimmey, J. M. & Stallings, C. L. Bacterial pathogens versus autophagy: implications for therapeutic interventions. *Trends Mol. Med.* **22**, 1060–1076 (2016).
161. Upadhyay, S., Mittal, E. & Philips, J. A. Tuberculosis and the art of macrophage manipulation. *Pathog. Dis.* <https://doi.org/10.1093/femspd/fty037> (2018).
162. Watson, R. O. et al. The cytosolic sensor cGAS detects *Mycobacterium tuberculosis* DNA to induce type I interferons and activate autophagy. *Cell Host Microbe* **17**, 811–819 (2015).
163. Franco, L. H. et al. The ubiquitin ligase Smurf1 functions in selective autophagy of *Mycobacterium tuberculosis* and anti-tuberculous host defense. *Cell Host Microbe* **21**, 59–72 (2017).
164. Bah, A. & Vergne, I. Macrophage autophagy and bacterial infections. *Front. Immunol.* **8**, 1483 (2017).
165. Jayaswal, S. et al. Identification of host-dependent survival factors for intracellular *Mycobacterium tuberculosis* through an siRNA screen. *PLoS Pathog.* **6**, e1000839 (2010).
166. Kim, J. J. et al. Host cell autophagy activated by antibiotics is required for their effective antimycobacterial drug action. *Cell Host Microbe* **11**, 457–468 (2012).
167. Watson, R. O., Manzanillo, P. S. & Cox, J. S. Extracellular *M. tuberculosis* DNA targets bacteria for autophagy by activating the host DNA-sensing pathway. *Cell* **150**, 803–815 (2012).
168. Wang, J. et al. MicroRNA-155 promotes autophagy to eliminate intracellular mycobacteria by targeting Rheb. *PLoS Pathog.* **9**, e1003697 (2013).
169. Liang, X. H. et al. Protection against fatal Sindbis virus encephalitis by beclin, a novel Bcl-2-interacting protein. *J. Virol.* **72**, 8586–8596 (1998).
170. Orvedahl, A. et al. Autophagy protects against Sindbis virus infection of the central nervous system. *Cell Host Microbe* **7**, 115–127 (2010).
171. Orvedahl, A. et al. HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein. *Cell Host Microbe* **1**, 23–35 (2007).
172. Mijaljica, D. & Klionsky, D. J. Autophagy/virophagy: a “disposal strategy” to combat COVID-19. *Autophagy* <https://doi.org/10.1080/15548627.2020.1782022> (2020).
173. Shojaei, S., Suresh, M., Klionsky, D. J., Labouta, H. I. & Ghavami, S. Autophagy and SARS-CoV-2 infection: a possible smart targeting of the autophagy pathway. *Virulence* **11**, 805–810 (2020).
174. Carmona-Gutierrez, D. et al. Digesting the crisis: autophagy and coronaviruses. *Microb. Cell* **7**, 119–128 (2020).
175. Choi, J. et al. The parasitophorous vacuole membrane of *Toxoplasma gondii* is targeted for disruption by ubiquitin-like conjugation systems of autophagy. *Immunity* **40**, 924–935 (2014).
176. Ghartey-Kwansah, G. et al. Autophagy in the control and pathogenesis of parasitic infections. *Cell Biosci.* **10**, 101 (2020).
177. O'Driscoll, M. et al. Age-specific mortality and immunity patterns of SARS-CoV-2. *Nature* <https://doi.org/10.1038/s41586-020-2918-0> (2020).
178. Gelino, S. et al. Intestinal autophagy improves healthspan and longevity in *C. elegans* during dietary restriction. *PLoS Genet.* **12**, e1006135 (2016).
179. Minnerly, J., Zhang, J., Parker, T., Kaul, T. & Jia, K. The cell non-autonomous function of ATG-18 is essential for neuroendocrine regulation of *Caenorhabditis elegans* lifespan. *PLoS Genet.* **13**, e1006764 (2017).
180. Bai, H., Kang, P., Hernandez, A. M. & Tatar, M. Activin signaling targeted by insulin/dFOXO regulates aging and muscle proteostasis in *Drosophila*. *PLoS Genet.* **9**, e1003941 (2013).
181. Carnio, S. et al. Autophagy impairment in muscle induces neuromuscular junction degeneration and precocious aging. *Cell Rep.* **8**, 1509–1521 (2014).
182. Horvath, S. DNA methylation age of human tissues and cell types. *Genome Biol.* **14**, R115 (2013).
183. Dong, S. et al. Chaperone-mediated autophagy sustains haematopoietic stem-cell function. *Nature* **591**, 117–123 (2021).
184. Bourdenx, M. et al. Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome. *Cell* **184**, 2696–2714 (2021).
185. Lautrup, S., Sinclair, D. A., Mattson, M. P. & Fang, E. F. NAD<sup>+</sup> in brain aging and neurodegenerative disorders. *Cell Metab.* **30**, 630–655 (2019).
186. Franceschi, C., Garagnani, P., Parini, P., Giuliani, C. & Santoro, A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. *Nat. Rev. Endocrinol.* **14**, 576–590 (2018).
187. Medzhitov, R. Origin and physiological roles of inflammation. *Nature* **454**, 428–435 (2008).
188. Riffelmacher, T., Richter, F. C. & Simon, A. K. Autophagy dictates metabolism and differentiation of inflammatory immune cells. *Autophagy* **14**, 199–206 (2018).
189. Swanson, K. V., Deng, M. & Ting, J. P. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. *Nat. Rev. Immunol.* **19**, 477–489 (2019).
190. Sun, Q., Fan, J., Billiar, T. R. & Scott, M. J. Inflammasome and autophagy regulation—a two-way street. *Mol. Med.* **23**, 188–195 (2017).
191. Menzies, F. M. et al. Autophagy and neurodegeneration: pathogenic mechanisms and therapeutic opportunities. *Neuron* **93**, 1015–1034 (2017).
192. Rubinsztein, D. C., Codogno, P. & Levine, B. Autophagy modulation as a potential therapeutic target for diverse diseases. *Nat. Rev. Drug Discov.* **11**, 709–730 (2012).
193. Wood, J. G. et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. *Nature* **430**, 686–689 (2004).

194. Morselli, E. et al. Spermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome. *J. Cell Biol.* **192**, 615–629 (2011).
195. Pietrocola, F. et al. Spermidine induces autophagy by inhibiting the acetyltransferase EP300. *Cell Death Differ.* **22**, 509–516 (2015).
196. Madeo, F., Eisenberg, T., Pietrocola, F. & Kroemer, G. Spermidine in health and disease. *Science* <https://doi.org/10.1126/science.aan2788> (2018).
197. Eisenberg, T. et al. Cardioprotection and lifespan extension by the natural polyamine spermidine. *Nat. Med.* **22**, 1428–1438 (2016).
198. Zhang, H. et al. Polyamines control eIF5A hypusination, TFEB translation, and autophagy to reverse B cell senescence. *Mol. Cell* **76**, 110–125 (2019).
199. Eisenberg, T. et al. Induction of autophagy by spermidine promotes longevity. *Nat. Cell Biol.* **11**, 1305–1314 (2009).
200. Song, H. L., Demirev, A. V., Kim, N. Y., Kim, D. H. & Yoon, S. Y. Ouabain activates transcription factor EB and exerts neuroprotection in models of Alzheimer's disease. *Mol. Cell. Neurosci.* **95**, 13–24 (2019).
201. Huang, R. et al. Deacetylation of nuclear LC3 drives autophagy initiation under starvation. *Mol. Cell* **57**, 456–466 (2015).
202. Lee, I. H. et al. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. *Proc. Natl Acad. Sci. USA* **105**, 3374–3379 (2008).
203. Fang, E. F. Mitophagy and NAD<sup>+</sup> inhibit Alzheimer disease. *Autophagy* **15**, 1112–1114 (2019).
204. Mouchiroud, L. et al. The NAD<sup>+</sup>/Sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. *Cell* **154**, 430–441 (2013).
205. Zhang, H. et al. NAD<sup>+</sup> repletion improves mitochondrial and stem cell function and enhances life span in mice. *Science* **352**, 1436–1443 (2016).
206. Mitchell, S. J. et al. Nicotinamide improves aspects of healthspan, but not lifespan, in mice. *Cell Metab.* **27**, 667–676 (2018).
207. Ryu, D. et al. Urolithin A induces mitophagy and prolongs lifespan in *C. elegans* and increases muscle function in rodents. *Nat. Med.* **22**, 879–888 (2016).
208. Andreux, P. A. et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. *Nat. Metab.* **1**, 593–603 (2019).
209. Escobar, K. A., Cole, N. H., Mermier, C. M. & VanDusseldorp, T. A. Autophagy and aging: maintaining the proteome through exercise and caloric restriction. *Aging Cell* **18**, e12876 (2019).
210. de Cabo, R. & Mattson, M. P. Effects of intermittent fasting on health, aging, and disease. *N. Engl. J. Med.* **381**, 2541–2551 (2019).
211. Alexander-Floyd, J. et al. Unexpected cell type-dependent effects of autophagy on polyglutamine aggregation revealed by natural genetic variation in *C. elegans*. *BMC Biol.* **18**, 18 (2020).
212. Bjedov, I. et al. Fine-tuning autophagy maximises lifespan and is associated with changes in mitochondrial gene expression in *Drosophila*. *PLoS Genet.* **16**, e1009083 (2020).
213. Mulcahy Levy, J. M. & Thorburn, A. Autophagy in cancer: moving from understanding mechanism to improving therapy responses in patients. *Cell Death Differ.* **27**, 843–857 (2020).
214. Park, C. & Cuervo, A. M. Selective autophagy: talking with the UPS. *Cell Biochem. Biophys.* **67**, 3–13 (2013).
215. Yang, S. et al. Pancreatic cancers require autophagy for tumor growth. *Genes Dev.* **25**, 717–729 (2011).
216. Piffoux, M., Eriau, E. & Cassier, P. A. Autophagy as a therapeutic target in pancreatic cancer. *Br. J. Cancer* **124**, 333–344 (2021).
217. Matsuura, A., Tsukada, M., Wada, Y. & Ohsumi, Y. Apg1p, a novel protein kinase required for the autophagic process in *Saccharomyces cerevisiae*. *Gene* **192**, 245–250 (1997).
218. Alvers, A. L. et al. Autophagy is required for extension of yeast chronological life span by rapamycin. *Autophagy* **5**, 847–849 (2009).
219. Rana, A. et al. Promoting Drp1-mediated mitochondrial fission in midlife prolongs healthy lifespan of *Drosophila melanogaster*. *Nat. Commun.* **8**, 448 (2017).
220. Velikkakath, A. K., Nishimura, T., Oita, E., Ishihara, N. & Mizushima, N. Mammalian Atg2 proteins are essential for autophagosome formation and important for regulation of size and distribution of lipid droplets. *Mol. Biol. Cell* **23**, 896–909 (2012).
221. Xu, P. et al. Atg2, Atg9 and Atg18 in mitochondrial integrity, cardiac function and healthspan in *Drosophila*. *J. Mol. Cell. Cardiol.* **127**, 116–124 (2019).
222. Maruyama, T. & Noda, N. N. Autophagy-regulating protease Atg4: structure, function, regulation and inhibition. *J. Antibiot.* <https://doi.org/10.1038/ja.2017.104> (2017).
223. Yang, J. et al. MiR-34 modulates *Caenorhabditis elegans* lifespan via repressing the autophagy gene *atg9*. *Age* **35**, 11–22 (2013).
224. Reggiori, F. & Klionsky, D. J. Autophagosomes: biogenesis from scratch? *Curr. Opin. Cell Biol.* **17**, 415–422 (2005).
225. Ruckenstein, C. et al. Lifespan extension by methionine restriction requires autophagy-dependent vacuolar acidification. *PLoS Genet.* **10**, e1004347 (2014).
226. Bjedov, I. et al. Mechanisms of life span extension by rapamycin in the fruit fly *Drosophila melanogaster*. *Cell Metab.* **11**, 35–46 (2010).
227. Jia, K. & Levine, B. Autophagy is required for dietary restriction-mediated life span extension in *C. elegans*. *Autophagy* **3**, 597–599 (2007).
228. Hars, E. S. et al. Autophagy regulates ageing in *C. elegans*. *Autophagy* **3**, 93–95 (2007).
229. He, C. & Klionsky, D. J. Regulation mechanisms and signaling pathways of autophagy. *Annu. Rev. Genet.* **43**, 67–93 (2009).
230. Walczak, M. & Martens, S. Dissecting the role of the Atg12–Atg5–Atg16 complex during autophagosome formation. *Autophagy* **9**, 424–425 (2013).
231. Teter, S. A. et al. Degradation of lipid vesicles in the yeast vacuole requires function of Cvt17, a putative lipase. *J. Biol. Chem.* **276**, 2083–2087 (2001).
232. Tang, F. et al. A life-span extending form of autophagy employs the vacuole–vacuole fusion machinery. *Autophagy* **4**, 874–886 (2008).
233. Rieter, E. et al. Atg18 function in autophagy is regulated by specific sites within its  $\beta$ -propeller. *J. Cell Sci.* **126**, 593–604 (2013).
234. McQuary, P. R. et al. *C. elegans* S6K mutants require a creatine-kinase-like effector for lifespan extension. *Cell Rep.* **14**, 2059–2067 (2016).
235. Narendra, D., Tanaka, A., Suen, D. F. & Youle, R. J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. *J. Cell Biol.* **183**, 795–803 (2008).
236. Rana, A., Rera, M. & Walker, D. W. Parkin overexpression during aging reduces proteotoxicity, alters mitochondrial dynamics, and extends lifespan. *Proc. Natl Acad. Sci. USA* **110**, 8638–8643 (2013).
237. Zhuang, N., Li, L., Chen, S. & Wang, T. PINK1-dependent phosphorylation of PINK1 and parkin is essential for mitochondrial quality control. *Cell Death Dis.* **7**, e2501 (2016).
238. Schiavi, A. et al. Iron-starvation-induced mitophagy mediates lifespan extension upon mitochondrial stress in *C. elegans*. *Curr. Biol.* **25**, 1810–1822 (2015).
239. Johansen, T. & Lamark, T. Selective autophagy mediated by autophagic adapter proteins. *Autophagy* **7**, 279–296 (2011).
240. Parekh, V. V. et al. Autophagy-related protein Vps34 controls the homeostasis and function of antigen cross-presenting CD8 $\alpha^+$  dendritic cells. *Proc. Natl Acad. Sci. USA* **114**, E6371–E6380 (2017).
241. Cabreiro, F. et al. Metformin retards aging in *C. elegans* by altering microbial folate and methionine metabolism. *Cell* **153**, 228–239 (2013).
242. Partridge, L., Fuentealba, M. & Kennedy, B. K. The quest to slow ageing through drug discovery. *Nat. Rev. Drug Discov.* **19**, 513–532 (2020).
243. Lu, Y. X. et al. A TORC1-histone axis regulates chromatin organisation and non-canonical induction of autophagy to ameliorate ageing. *eLife* **10**, e62233 (2021).
244. Fivenson, E. M. et al. Mitophagy in neurodegeneration and aging. *Neurochem. Int.* **109**, 202–209 (2017).
245. Honda, Y., Tanaka, M. & Honda, S. Trehalose extends longevity in the nematode *Caenorhabditis elegans*. *Aging Cell* **9**, 558–569 (2010).
246. Shi, D. et al. The precursor of PI(3,4,5)P<sub>3</sub> alleviates aging by activating *daf-18(Pten)* and independent of *daf-16*. *Nat. Commun.* **11**, 4496 (2020).

## Acknowledgements

E.F.F. was supported by HELSE SØR-ØST (2017056, 2020001 and 2021021), the Research Council of Norway (262175 and 277813), the National Natural Science Foundation of China (81971327), Akershus University Hospital (269901 and 261973), the Civitan Norges Forskningsfond for Alzheimers sykdom (for a three-year PhD fellowship, 281931), the Czech Republic–Norway KAPPA programme (with M. Vyhnaček, TO01000215) and the Rosa sløyfe/Norwegian Cancer Society & Norwegian Breast Cancer Society (207819). J.L. is supported by a BBSRC David Phillips Fellowship (BB/P005535/1), a BBSRC Responsive Mode Grant (BB/T013273/1), an AMS Springboard Award (SBF004\1051) and a Wellcome Trust ISSF award (ISSF3/H17RCO/NG18). A.K.S. is supported by Wellcome Trust Investigator Award 103830/Z/14/Z. A.S. is supported by the Norwegian Cancer Society (171318) and the Research Council of Norway (221831) and its Centres of Excellence funding scheme (262652), as well as by HELSE SØR-ØST (2020032). T.J. is supported by the Norwegian Cancer Society (190214) and the Research Council of Norway (249884). N.T. was supported by grants from the European Research Council (ERC GA695190, MANNA; ERC-GA737599, NeuronAgeScreen). M.H. is supported by the National Institutes of Health (AG038664 and GM117466) as well as by the American Federation for Aging Research and the Larry L. Hillblom Foundation. R.M. is supported by the National Institutes of Health (AG057296 and AG054407), the Tau Consortium and the Daniel F. and Ada L. Rice Foundation. D.C.R. is supported by the UK Dementia Research Institute (funded by the MRC), Alzheimer's Research UK and the Alzheimer's Society (UKDRI-2002 to D.C.R.), the Tau Consortium, Alzheimer's Research UK, an anonymous donation to the Cambridge Centre for Parkinson-Plus and the Roger de Spoelberch Prize. I.B. is supported by funding from the European Research Council (ERC PoC 842174) and the Cancer Research UK City of London Centre Award (C7893/A28990). L.P. is supported by a Wellcome Trust Collaborative Award, the Max Planck Society and the European Research Council under the European Union's Seventh Framework Programme (FP7/2007–2013)/ERC grant agreement number 268739. G.K. is supported by the Ligue contre le Cancer (équipe labellisée); Agence Nationale de la Recherche (ANR) – Projets blancs; AMMICA US23/CNRS UMS3655; Association



pour la recherche sur le cancer (ARC); Association "Ruban Rose"; Cancéropôle Ile-de-France; Fondation pour la Recherche Médicale (FRM); a donation by Elior; Equipex Onco-Pheno-Screen; European Joint Programme on Rare Diseases (EJPRD); Gustave Roussy Odyssey, the European Union Horizon 2020 Projects Oncobiome and Crimson; Fondation Carrefour; Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LabEx Immuno-Oncology (ANR-18-IDEX-0001); the Leducq Foundation; the RHU Torino Lumière; Seerave Foundation; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and SIRIC Cancer Research and Personalized Medicine (CARPEM). This study contributes to the IdEx Université de Paris ANR-18-IDEX-0001. All figures were created with [BioRender.com](https://www.biorender.com).

### Competing interests

E.F.F. has a CRADA arrangement with ChromaDex and is a consultant to Aladdin Healthcare Technologies, the Vancouver Dementia Prevention Centre and Intellectual Labs. A.K.S. is a consultant to Oxford Healthspan. D.C.R. is a consultant for Aladdin Healthcare Technologies, Drishti Discoveries and Nido Biosciences. G.K. is a scientific

co-founder of everImmune, Samsara Therapeutics and Therafast Bio. All other authors declare no competing interests.

### Additional information

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s43587-021-00098-4>.

**Correspondence** should be addressed to J.L. or E.F.F.

**Peer review information** *Nature Aging* thanks Louis Lapierre, Esther Wong and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© Springer Nature America, Inc. 2021